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Summary 
Angiogenesis is the formation of new blood vessels from pre-existing capillaries. It 
occurs throughout the life of higher organisms, in both health and disease. Meta-
bolically active tissues in the body are found in the proximity of the blood capillaries, 
formed by the process of angiogenesis. The idea that control of angiogenesis could 
have a therapeutic potential has raised great interest during the past 40 years. Stim-
ulation of angiogenesis can be therapeutic for ischemic heart disease, peripheral 
arterial disease and wound healing. Decreasing or inhibiting angiogenesis can be a 
therapeutic goal in cancer, some ophthalmic pathological conditions, rheumatoid 
arthritis, and other diseases. 
Vascular Endothelial Growth Factors (VEGFs) and their receptors (VEGFRs) are major 
players in both physiological and pathological angiogenesis. VEGFs constitute a fam-
ily of proteins that play important roles in blood and lymphatic vessel development. 
VEGFs bind VEGFR-1, -2, and -3, promoting cell survival, proliferation, differentiation, 
and migration. VEGFR-2 is the major mediator of angiogenic signaling in endothelial 
cells, and its activity is regulated at multiple levels. Ligand binding to the extracellular 
domain (ECD) of VEGFR-2 leads to receptor dimerization, followed by intracellular 
kinase domain activation, receptor internalization and downstream signaling. 
The goal of this study was to develop novel antiangiogenic drugs targeting VEGFR-2, 
as an addition or alternative to existing cancer therapies. As for targeting tools, we 
used different antibody formats and antibody-like molecules. In this study, we gen-
erated and tested three types of ECD binders, single chain fragment variable anti-
bodies (scFvs), fragment antigen-binding antibodies (Fabs) and full-length Immuno-
globulins G (IgGs), specifically interacting with single Ig-homology domains, located 
in the receptor ECD. We identified several promising antibodies, interacting with 
the ECD of VEGFR-2 and blocking ligand-stimulated receptor activation. Different 
formats of antibodies showed similar effects with significant inhibition of VEGFR-2 
phosphorylation at Tyr1175 and phosphorylation of PLC-γ, as well as inhibition of in 
vitro angiogenesis in Human Umbilical Vein Endothelial cell (HUVEC) tube formation 
and HUVEC migration assays. Our findings provide the proof-of-principle that highly 
specific anti-VEGFR-2 agents targeting the membrane-proximal Ig-domains D4 and 
D7 inhibit receptor activity. 
Interestingly, the binding of antibody fragments to VEGFR-2 led to receptor internal-
ization as demonstrated by an increase in total volume of intracellular receptor-pos-
itive vesicles. Internalization independent of ligand binding represents a new, prom-
ising property of these VEGFR-2 antibodies. The new agents will be useful for in vivo 
studies aimed at vessel imaging or at inhibiting VEGFR-2 signaling. 
Additionally, we tested the already characterized Designed Ankyrin Repeat Proteins 
(DARPins) for tumor targeting in vivo.

Zusammenfassung
Angiogenese bezeichnet die Sprossung und Spaltung von existierenden Blutgefäßen. 
Dies ist ein permanenter Prozess in höheren Organismen und findet in gesundem so-
wie in krankem Zustand statt. Die Blutgefäßformierung ist besonders hoch in direkter 
Umgebung zu metabolisch aktivem Gewebe, wie den Orangen. Während der letzten 40 
Jahren fand bereits intensive Forschung im Bereich der Angiogenese statt, da ein gross-
es Potential in der gerichteten Bildung von neuen Blutgefäßen gesehen wird und den 
daraus folgenden therapeutischen Effekten. Die ischämischen Herzkrankheiten, peri-
pheren arteriellen Verschlusskrankheiten und Wundheilung sind dabei die wichtigsten 
potentiellen Anwendungsgebiete. Partielle oder vollständige Inhibierung von Angioge-
nese sind mögliche therapeutische Maßnahmen im Kampf gegen Krebs, einigen patho-
logischen Bedingungen, rheumatoider Arthritis und andere Krankheiten.
Die vaskulären endothelialen Wachstumsfaktoren (VEGFs) und dessen Rezeptoren 
(VEGFRs) sind dabei die wichtigsten Partner in physiologischer als auch pathologischer 
Angiogense. VEGFs spielen eine essentielle Rolle in der Bildung von Blut- und Lymph-
gefäßen. VEGFs interagieren mit allen drei VEGFRs (VEGFR-1, 2 und -3) und stimulieren 
Proliferation, Differenzierung und Migration.  VEGFR-2 ist vor allem verantwortlich für 
agiogene Aktivität in Endothelzellen. Dessen Aktivität wird schrittweise reguliert. Die Bin-
dung vom VEGF an die extrazelluläre Domäne von VEGFR-2 führt zu dessen Dimerisie-
rung, gefolgt von der Aktivierung der intrazellulären Kinasedomäne, welche die Interna-
lisierung und weitere Signalwege aktiviert. 
Das Ziel dieser Doktorarbeit war es eine neue anti-angiogene Therapierung des VEGR-2 
zu entwickeln, die als zusätzliche oder alternative Maßnahme im Kampf gegen Krebs 
eingesetzt werden kann. Der Fokus liegt dabei auf dem möglichen Einsatz von ver-
schiedenen Antikörpervarianten bzw. antikörper-ähnlichen Proteinen. Während dieser 
Studie wurden drei verschiedene Typen von ECD Bindern erzeugt und getestet: Ein-
zellketten-Antikörper (scFvs), Antigen-bindendes Antikörperfragment (Fab) und intaktes 
Immunoglobulin G (lgG).  Es ist uns gelungen mehrere potenzielle Antikörper zu iden-
tifizieren, die mit der EC Domäne von VEGFR-2 interagieren und dabei die Interaktion 
mit dessen Liganden VEGF blockieren. Die verschiedenen getesteten Interaktionspart-
ner wiesen alle eine signifikante Inhibierung von der VEGFR-2 Phosphorylierungsstelle 
Tyr1175 und Phosphorylierung von PLC- γ auf. Des weiteren konnte eine deutliche Inhi-
bierung von in vitro Angionese in humanen Nabelvenen-endothel Zellen (HUVEC) regist-
riert werden. Es ist uns gelungen hoch spezifische Antikörper bzw. Antikörper-ähnlichen 
Proteinen zu erzeugen, die spezifisch an die lg-Domäne D4 und D7 VEGFR-2 binden.
Die Bindung der Antikörperfragmente führte zu einer Internalisierung des VEGFR-2, 
welches durch ein höheres Ausmaß intrazellulärer Rezeptorvesikel bestätigt wurde. Die 
gesteuerte Internalisierung des Rezeptors in der Abwesenheit von VEGF öffnet neue po-
tenzielle therapeutische Maßnahmen. Die Antikörper bieten ein nützliches Instrument 
für in vivo Studien im Bereich Imaging oder zur Inhibierung von VEGFR-2 Signalweges.
Darüber hinaus haben wir die bereits charakterisierten Designed Ankyrin Repeat Pro-
tein (DARPins) für die gezielte Tumorbehandlung in vivo getestet.
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AA  Amino acid
AMD  Age-related macular degeneration
AP  Alkaline phosphatase
BSA   Bovine serum albumin
CDR   Complimentarity determining region 
CH / CL   Antibody heavy/light chain constant region 
DARPins  Designed Ankyrin Repeat Proteins
DMEM   Dulbecco’s modified eagle’s medium
DMSO  Dimethyl sulfoxide
DTT   Dithiothreitol
EC   Endothelial cells
ECD  Extracellular domain
ECM   Extracellular matrix 
E. coli   Escherichia coli
EDTA   Ethylenediamine tetraacetic acid
EGF   Epidermal growth factor 
EGFR  Epidermal growth factor receptor
ELISA  Enzyme linked immunosorbent assay
Erk   Extracellular signal-regulated kinase
Fab   Fragment antigen-binding antibody
Fc  Fragment crystallisable 
FDA   Food and Drug Administration 
FGF   Fibroblast growth factor 
Flk-1   Fetal liver kinase-1 = murine VEGFR-2
Fv   Variable fragment
HEK293   Human embryonic kidney cells 293
HEPES  4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid
HRP  Horseradish peroxidase
Ig   Immunoglobulin 
IPTG  Isopropyl β-D-1-thiogalactopyranoside
KDR  Kinase insert domain receptor
mAb   Monoclonal antibody 
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OD600  Optical density at 600 nm wavelength
PAEC   Porcine aortic endothelial cells
PAE KDR  Porcine aortic endothelial cells overexpressing VEGFR-2
PBS   Phosphate buffered saline
PCR   Polymerase chain reaction
PEG  Polyethylene glycol
PEI  Polyethylenimine
PET  Positron emission tomography
PEM  Protein expressing medium
PLCγ   Phospholipase C gamma
PVDF   Polyvinylidene fluoride
RT   Room temperature 
RTK   Receptor tyrosine kinase 
ScFv   Single chain variable fragment
SDS-PAGE  Sodium dodecylsulfate polyacryl gel electrophoresis 
SEC  Size-exclusion chromatography
SH2   Src homology-2 domain
SHB   Src homology-2 protein in beta-cells
SPECT  Single photon emission computed tomography
SVEGFR   Soluble VEGFR
TBST  Tris buffered saline with 0.1% Tween 20
VEGF   Vascular endothelial growth factor 
VEGFR   VEGF receptor 
VH / VL   Antibody heavy/light chain variable region
History of single chain 
fragment variable 
(scFvs) antibodies 
development 
1
20 Dragana Avramović, Doctoral thesis
Abstract
Introduction
As high affinity, protein-based binding reagents, antibodies have proven to be the 
superior choice in many applications in biological research, medical therapy, and 
diagnosis. The development of monoclonal antibodies (mAbs) and its standardized 
production, led to regulatory approvals for IgGs as treatment options for cancer, 
infectious and inflammatory disease, in the last two decades. Recombinant mAbs 
expressed in a form of smaller binding fragments solved some of the issues encoun-
tered with full-length Immunoglobulins G (IgGs) and alleviated problems such as the 
high costs, demanding production schemes and low tissue penetration due to IgGs’ 
large size. Easier selection and genetic manipulation of antibody fragments enabled 
such antibodies to become part of standard laboratory practice to produce com-
pletely functional antigen-binding fragments in bacterial systems. The focus on struc-
tural designs led to improved in vivo pharmacokinetics, extended recombinant library 
generation and enabled selection against challenging targets. At the same time, new 
molecular strategies have enhanced affinity, stability and expression levels. The sim-
plicity of the technique allowed agile development of the method and led to the de-
velopment of small antibody fragments. Such ScFvs can be fused to marker proteins 
(fluorescent proteins, alkaline phosphatase, radionuclides), can be expressed in the 
form of bifunctional scFvs with two antigen specificities and can be formatted to larg-
er formats (Fabs, Fab2, IgG). Alternatively, antibody fragments could also be used 
in the immunotoxin construction, for therapeutic gene delivery and generation of 
anticancer intrabodies for therapeutic purposes. Redesigned mAb-based fragments 
provide the next generation of antibody-based reagents for immunotherapy and in 
vivo imaging, with many having being tested in late-phase clinical trials. 
Antibodies are an integral part of the immune defense system that identifies and 
neutralizes foreign or innate objects such as bacteria, viruses or infected cells, which 
represent a threat to the system. An antibody carries an antigen-binding site (para-
tope) that recognizes a unique target-specific antigen (epitope). Paratope specifical-
ly binds the epitope. (Figure 1.1, A). This highly precise mechanism allows an anti-
body to neutralize microbes as well as to target infected cells that are then further 
recognized and attacked by other components of the immune system1. The most 
abundant type of antibody is immunoglobulin G (IgG)2, a large molecule of about 
150 kDa that consists of two distinct regions: the fragment antigen-binding (Fab) 
and fragment crystallizable (Fc) part. The Fab fragment consists of a constant (CL) 
1.1.
1.2.
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Recombinant antibody 
technology
and a variable (VL) light-chain domain, linked to the constant (CH) and the variable 
(VH) heavy chain domains (Figure 1.1, B). VL and VH carry each three solvent-exposed 
loops that bind the antigen, named complementary determining regions (CDRs, Fig-
ure 1.1, C). Today researchers can select antibodies against virtually any target; it is 
not surprising that these molecules and their small conjugates are used extensively 
in clinical and basic research.
The immune system relies on antibodies. This important role in first line defense is 
possible due to the diversity of antibody molecules and their high antigen specificity. 
The immense diversity is achieved through somatic recombination and hypermuta-
genesis of a set of variant genes5 (Figure 1.2, A). These unique properties of antibod-
ies proved to be an attractive tool in research, medical diagnosis and therapy6. Fur-
ther development of the field led to the manipulation of the affinity and specificity 
of antigen binding by mimicking naturally occurring somatic hypermutation during 
an immune response. It opened new possibilities for replacing the existing practices 
of animal immunization applying hybridoma technology (Figure 1.2, B). In 1975, the 
era of hybridoma technology began with the results of Köhler and Milstein7. In 1984, 
their work was awarded the Nobel Prize in Medicine. Their findings led to the devel-
opment of monoclonal antibodies with defined specificity, and consistent quality in 
large scale production. 
Monoclonal antibody therapy faced several difficulties: monoclonal antibodies are 
almost exclusively of murine origin and are thus recognized as foreign by the human 
Figure 1.1. Antibody structure. A) IgG structure representation with the focus on paratope-epitope binding 
adapted from3. B) Overall crystal structure of intact antibody protein with the focus on Fab and Fc parts and 
complementary determining regions (CDRs) adapted from4.
1.3.
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immune system. Delivery of mature immunoglobulin requires extensive post-trans-
lational modifications (disulfide bond formation and glycosylation). Due to the large 
size and molecular complexity of full-size antibodies, their production requires 
mammalian expression systems8, which is time-consuming and costly. Primary at-
tempts to move antibody production from hybridoma cells to bacteria failed due to 
challenges such as improper folding of the polypeptide and consequent aggrega-
tion in the cytoplasm of bacterial cells9,10. Monoclonal antibodies provided additional 
formats of antibodies with different application possibilities (Fab, or Fv fragments). 
ScFv antibodies
In 1988 scFv antibodies were reported for the first time as the minimal form of anti-
body13. The Fv fragment is the smallest unit of an immunoglobulin molecule that can 
recognize an antigen and that consists of variable domains of heavy (VH) and light (VL) 
chains joined by a flexible peptide linker (Figure 1.3 A, B). With a size of 28 kDa, scFvs 
can be functionally expressed in E. coli. Simple protein expression additionally allows 
improvement of scFvs properties, including their affinity, by protein engineering14. 
ScFv is a covalently linked heterodimer of heavy and light chain variable domains de-
rived from hybridoma13,15-17, spleen cells from immunized mice18-20, or B lymphocytes 
from humans21-23. MRNA is isolated from antibody-producing cells and reversely tran-
scribed into cDNA to serve as a template for DNA amplification by PCR. This enabled 
construction of large libraries with a diverse range of antibody genes22. 
Figure 1.2. IgG technology. A) Schematic representation of V(D)J recombination and somatic hypermutation 
adapted from11. B) Scheme of hybridoma technology developed by Georges Köhler and César Milstein 1970. 
The figure was adapted from12.
1.3.1.
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Expression of scFv antibodies
Phage display using recombinant libraries
To date, scFvs have been successfully expressed in different expression systems 
such as bacteria, mammalian cells24, yeast25, plant cells15 and insect cells26. Each ex-
pression system demonstrates advantages and disadvantages in the production of 
active scFvs. Correct folding and secretion of the scFvs remain the critical criteria. 
Nevertheless, the bacterial expression system remains preferable for the produc-
tion of scFv antibody fragments among the various expression strategies available. 
The use of E. coli, as an easy and well-established expression system allows proper 
folding of scFvs and represents a simple technique applicable in a standard molec-
ular biology laboratory at low cost. 
This approach allows the optimization of both screening27 and protein production28. 
Challenges when using E. coli as expression system include the reducing environ-
ment of the bacterial cytoplasm which leads to insoluble aggregate and inclusion 
body formation29,30. The inclusion bodies must be renatured and the scFvs correct-
ly folded in vitro8 which complicates the expression procedure. This problem was 
overcome with the introduction of a signal peptide into the expression vectors to 
direct scFvs into the periplasmic space located between the inner and the outer 
membrane31,32. This periplasmic space contains proteins such as chaperones and 
disulfide isomerases, which assist proper folding of recombinant proteins33.
New techniques opened the opportunity for in vitro selection of scFvs from large 
libraries of variable domains, avoiding the traditional hybridoma method. In 1985, 
Smith37 postulated that foreign DNA could be fused to the gene encoding the pIII 
coat protein of a nonlytic filamentous phage. The protein is then expressed as a 
fusion protein on the phage surface without disturbing the infectivity of the virus 
(Figure 1.3, C). McCafferty et al.38 have demonstrated that scFv fragments can be 
displayed on the phage surface as functional proteins, retaining antigen-binding 
capability. This technology allows rare clones to be selected and isolated from a 
large population of phages using any desirable antigen39. After this breakthrough 
discovery, the technology has been widely exploited for the production of antibody 
fragment molecules including Fab fragments40, Fv fragments41, and their derivates42.
Based on the source of antibody genes, scFv libraries can be immune, naïve, and 
synthetic.
1. Immune libraries are derived from variable domains of antibody genes of 
B cells from an immunized animal (mouse, rabbit, rat, goat, camel, sheep, 
donkey). Therefore, this approach always results in higher affinities of iso-
lated binders as well as a greater number of antigen-specific binders 
than antibodies derived from naïve libraries. However, the construction 
1.3.2.
1.3.3.
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Figure 1.3. ScFvs and display technologies. A) Overview of engineered antibodies and antibody fragments 
engineered for clinical application adapted from34. B) Cristal structure of scFv adapted from35. C) A schematic 
of an affinity-based selection procedure adapted in phage display technology adapted from36. D) A schemat-
ic representation of a ribosome display selection process adapted from Creative BioLabs 
(http://www.creative-biolabs.com).
of a new library for each antigen is necessary. Antibodies from immune li-
braries are biased towards the antigen that was used for immunization. 
2.  Naïve libraries are derived from nonimmunized B cells and constructed from 
a pool of IgM genes43,44. A single library can be utilized for any antigen. The 
selected antibodies demonstrate various specificities. Naïve libraries are 
not biased towards any antigen. Such libraries are particularly useful for the 
production of antibody fragments difficult to generate with hybridoma tech-
nology, particularly against nonimmunogenic or toxic antigens. The affinities 
of scFv isolated from naive libraries are typically lower compared to those 
isolated from immune libraries14,43-45.
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3. Synthetic libraries are also derived from nonimmune sources, assembled syn-
thetically by combining the gene sequences from germ lines with randomized 
complementary determining regions (CDRs) responsible for antigen binding14,46. 
The majority of synthetic human antibody libraries rely on randomizing CDR3, 
the region which shows the largest diversity and which is directly responsible 
for antigen binding. These libraries provide high-affinity monoclonal antibod-
ies and are therefore extensively used today. A large number of semisynthetic 
libraries are also available; one of the largest is the Griffin-1 library with a total 
diversity of 1.2 × 109 scFv fragments (H Griffin, MRC, Cambridge, UK). 
Ribosomal display technology 
Affinity maturation of scFvs selected from 
phage display libraries
Antigen exposure for the scFvs selection 
process
Besides phage display, there are also libraries using ribosomal display technology 
for antibody selection. They use an in vitro method of isolating scFvs directly without 
involving phages and bacteria (Figure 1.3, D). The DNA library of scFv is transcribed 
and translated in vitro to create complexes of linked mRNA-ribosome-scFv proteins. 
Such complexes are used for selection on immobilized antigen. The mRNAs specifi-
cally recognizing the antigen are eluted, reversely transcribed and finally employed 
for the next round of selection47,48. 
Phage display technology favors the selection of phages from a significant number 
of clones that can bind to the target of interest with high affinity. This is achieved 
by multiple rounds of exposing phages to the antigen, washing steps to remove 
the unbound phage and elution of specifically bound phages. The eluted phages 
are amplified E. coli and used in the next round of selection. After the third round, 
infected E. coli is diluted and plated to yield single colonies. Single colonies are ran-
domly selected, and the phage is tested for antigen binding. The best binders are 
identified, expressed in large quantities and characterized.
To properly present the desired epitope, there are various ways to expose the anti-
gen to phage particles49. In the majority of protocols, the antigen is immobilized on 
a solid surface, such as an immunotube46, a microtiter plate well14, a BIAcore sensor 
chip50, or a column14. Alternatively, the antigen can be biotinylated in solution, where 
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the antigen-phage complex is captured on a streptavidin surface14.
Unique advantages of phage display technologies come to light when the antigen is 
not available or is unknown, when antibodies are selected against whole cells, tissue 
fragments or heterogeneous antigen mixture51-53. 
Advantages of scFv antibodies over full-
size monoclonal antibodies
Medical application
ScFvs in tumor therapy
1.4.1.1.
1.4.1.
1.4.
1.3.7.
There are several benefits of phage-displayed scFv over full-size monoclonal anti-
bodies including inexpensive production in E. coli, easy gene manipulation54, and 
the lack of the requirement of immune response stimulation. The smaller scFv frag-
ments penetrate more rapidly and evenly into target tissues, e.g. tumors, in compar-
ison to whole antibodies and display lower retention times in nontarget tissue55-57. 
As scFvs are cleared from circulation more rapidly, exposure of the healthy tissue58-60 
is shorter, which makes such antibody fragments preferable for imaging and drug 
delivery, using radionuclides and drug coupled scFvs. Additionally, the steps of 
the scFvs selection and production protocol can be standardized and automated. 
Therefore such a strategy is used in high throughput approaches61.
Application of scFvs
Due to their favorable properties, scFvs are used in medicine, laboratory diagnosis, 
and research. Furthermore, new ways of utilizing scFvs have appeared in nonin-
vasive tumor labeling and detection. scFvs proved especially applicable in in vivo 
imaging, allowing real-time detection.
The exciting idea that monoclonal antibodies can specifically recognize extracellular 
markers expressed on tumor cells has been present for a while62,63. Its limitation in 
solid tumor application was quickly revealed, due to IgGs’ poor tissue penetration62. 
ScFvs were offered as an alternative with an improved tissue penetration. Tumor 
therapy using scFvs requires specific markers on tumor cells and is either aimed 
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ScFvs in tumor therapy
ScFvs as recombinant immunotoxins
ScFvs as cancer vaccine
ScFvs as anticancer intrabodies
at neutralizing the targeted protein or at efficiently delivering further therapeutic 
agents, such as toxins, drugs or siRNAs. 
One of the first applications of scFvs was the neutralization of targeted protein 
(receptors) on tumor cells or accompanying tissue (endothelium, extracellular ma-
trix). One successful example of a targeted neutralizing antibody is a humanized 
scFv-Fc (scFvFc or “minibody”) fusion protein derived from an anti-CCR4 monoclonal 
antibody (mAb) h1567. The CC chemokine receptor 4 (CCR4) ligands are highly ex-
pressed in several cancers, such as breast cancer, ovarian cancer and cutaneous 
T-cell lymphoma64-66, and represent well-characterized targets for tumor-therapy64.
ScFvs in the form of recombinant immunotoxins (RIT) serve to carry cytotoxic drugs 
to kill cancer cells67,68. RITs are hybrid proteins consisting of an scFv binding an anti-
gen on cancer cells and Pseudomonas exotoxin A69. Either alone or in combination 
with chemotherapy, a number of such RITs are undergoing clinical trials for different 
types of cancer malignancies68,69. Many antibody fragments were tested in clinical 
trials as toxin carriers (Table 1.1).
Antibody fragments also play a considerable role in cancer gene therapy. ScFvs 
serve as platforms delivering therapeutic agents. Two examples of such treatments 
are retroviral vectors that display anti-CEA-scFv against carcinoembryonic antigen 
(CEA) and deliver the therapeutic gene of nitric oxide synthase. As a result, this re-
combinant retrovirus can bind, infect and kill the CEA-expressing cancer cells70. Li et 
al.71 targeted Epidermal Growth Factor Receptor 2 (HER2) in breast cancer, which is 
overexpressed in 20% of invasive breast cancer cases72,73. A vaccine with anti-HER2 
specificity delivers therapy genes into breast cancer cells by integrating HER2-specif-
ic scFv as a DNA condensing fusion protein. Many antibody fragments were tested in 
clinical trials as cancer vaccines carrying therapeutic genes (Table 1.1).
Apart from immunotoxins and therapeutic gene delivery, scFvs can also be used 
as anticancer intrabodies. Numerous studies have reported that such antibodies, 
when they reach cells, specifically bind and neutralize a vast range of oncogene 
products or signaling molecules. Such treatments can inhibit tumor growth or trig-
ger apoptosis in tumor cells. Such an anti-HER2 intrabody was tested in phase I 
clinical trials. The treatment involved adenoviral-mediated gene therapy using an 
intrabody in the treatment of HER2-overexpressing ovarian cancer74. Another study 
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by Strube and Chen75 confirmed that anticyclin E (expressed in the nucleus of the 
breast cancer cell) scFv intrabody inhibits the growth of the targeted cells.
Name NP type Target Ligand Bioactive compound Indication Phase
SGT-53 Lipid Transferrin receptor
Anti-
transferrin 
receptor 
ScFv
p53 DNA Solid tumors Ib
SGT-94 Lipid Transferrin receptor
Anti-
transferrin 
receptor 
ScFv
RB94 DNA Solid tumors I
C225-ILS-
Dox Lipid EGFR
Cetuximab 
Fab Doxorubicin Solid tumors I
Erbitux-
EDVspac
Bacterially 
derived 
mini-cell
EGFR
Bispecific 
monoclonal 
antibody 
(mAb)
Paclitaxel Solid tumors II
MM-302 Lipid HER2 Anti-HER ScFv Doxorubicin
Breast 
cancer I
Lipovaxin-
MM Lipid
Dendritic cell 
CD209 dab
Melanoma 
antigens + 
IFNγ
Melanoma 
vaccine I
MCC-465 Lipid Uncharacter-ised (GAH)
Anti-GAH 
F(ab′)2 Doxorubicin
Metastatic 
stomach 
cancer
I
Anti-EGFR 
ILs-Dox Lipid EGFR
Cetuximab 
Fab Doxorubicin Solid tumors I
Table 1.1. A list of nanoparticle–antibody conjugates undergoing clinical trials adapted from Roy van der 
Meel 201376.
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Application of scFvs in neurodegenerative diseases
ScFvs against HIV infection
Alzheimer’s disease (AD)
Neurodegenerative diseases are a heterogeneous group of chronic disorders typi-
cally characterized by the progressive degeneration of the structure and function of 
the central nervous system or the peripheral nervous system. The ability of scFvs to 
cross the blood-brain barrier, to be overexpressed long-term in vivo, as well as their 
invisibility to the immune system, open the way for attractive new strategies for the 
treatment of neurodegenerative diseases.
ScFvs as vehicles for delivery of different drugs, siRNA and toxins are emerging as 
promising therapeutics for several diseases86,87. In HIV-infected mice, CD7 specif-
ic scFv was coupled with anti-viral siRNA suppressing HIV-1 infection. ScFv as an 
immune-nanoparticle (CD7 antibody conjugated with PLGA/HDAC inhibitor) targets 
and delivers the therapeutic drugs (histone deacetylase inhibitor (HDACi)) to CD4+ 
T-cells hiding latent HIV particles88. 
The accumulation of amyloid-β-peptide (Aβ) in the brain is the hallmark of the patho-
genesis of Alzheimer’s disease (AD)77,78. Over the last decade, antibodies have been 
introduced to target and reduce high levels of Aβ in the brain and neutralize its toxic 
effects79. Conventional immunotherapies employing full-length IgGs demonstrated 
promising potential of immunotherapy, but also caused a vast range of undesirable 
side effects such as meningoencephalitis, vasogenic edema or cerebral microhemor-
rhages in the mouse model and in humans80. Therefore, smaller antibody fragments 
that circumvent the immune response were explored in search of a safer and more 
efficient therapy79.
Ryan et al.81 observed that the expression of a human scFv directed against the N-ter-
minal region of Aβ in the triple transgenic AD mouse model (3× Tg mice, carrying 
PS1M146V, APPSw, and tauP301L mutations) resulted in the reduction of amyloid 
plaques. The amount of hyperphosphorylated tau, correlated with an improvement 
of cognitive functions, was assessed in the Morris Water Maze test. A rAAV encoding 
a scFv directed against the N-terminal epitope of Aβ, administered via an intramus-
cular injection, reduced amyloid deposition and cognitive impairment in the APPswe/
PS1dE9 double transgenic mice82,83. Frenkel et al.84 delivered a scFv expressed on a 
phage, which bound amyloid plaques in the hippocampus of Tg APP mice. More re-
cently, Cattepoel et al.85 showed that a preventive intranasal administration of a hu-
manized scFv directed against the C-terminal region of Aβ could reduce the number 
of amyloid plaques in the cortex of Alzheimer model mice.
1.4.1.2.
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In vivo imaging
Diagnostic applications
The small size of scFvs enables conjugation with radionuclides, quantum dots, 
nanoparticles, and fluorophores. They can provide a non-invasive tool to visualize 
the location and distribution of a particular target in vivo. Critical properties are 
pharmacokinetics, tissue penetration and blood clearance without compromising 
binding affinity. The scFv format combines all of the above criteria and thus rep-
resents an ideal imaging tool. Interestingly, despite posing a challenge for thera-
peutic applications, the fast clearance of scFvs is a much-desired property in in vivo 
diagnostic applications. Radionuclide-conjugated scFv fragments against tenascin-c 
were used for visualization of heart disease in a rat model89. Radiolabeled scFv spe-
cifically binding tenascin-c showed a higher uptake of radioactivity in infarcted myo-
cardium compared to the non-infarcted muscle. Fluorescent complexes of quantum 
dots and anti-EGFR or anti-HER2/neu scFv antibodies enabled visualization of can-
cer cells56. Moreover, Quantum dot-anti-GRP78 scFv (Qdot-GRP78) not only visu-
alized the tumor but also demonstrated biological anti-tumor activity by inhibiting 
breast cancer growth in a xenograft model90. scFvs specific for histone H3 lysine 
9 acetylation (H3K9ac), fused with green fluorescent protein (minibodies), tracked 
post-translational histone modification in vivo in fruit fly and zebrafish91. Recently, 
a scFv-based technique (SunTag) was employed for long-term fluorescent imaging 
of single protein molecules in living cells by recruiting up to 24 copies of GFP. Ad-
ditionally, SunTag can be used to create a potent synthetic transcription factor by 
recruiting multiple copies of a transcription activation domain fused to a scFv target-
ing nuclease-deficient CRISPR/Cas9 protein and thus activating endogenous gene 
expression92. ScFvs can be used to improve the sensitivity of magnetic resonance 
imaging (MRI). scFv specific for carcinoembryonic antigen (CEA) conjugated to su-
pramagnetic iron oxide nanoparticles (SPIONs) could be used to target and image 
cancer cells more efficiently than the standard MRI technique93.
Another important application of scFvs is in the field of immunodiagnostics, where 
antibody fragments are increasingly replacing “conventional” immunodiagnostic re-
agents94. Highly specific antibody fragments recognize a variety of antigens such as 
proteins, nucleic acids, carbohydrates, lipids, but also entire pathogens. ScFvs can 
be used in numerous immunoassays (immunoblotting, ELISA, immunohistochemical 
staining and lateral flow immunochromatographic assays)95. Antibodies are detect-
ed using secondary antibodies recognizing a specific tag fused to the C- or N-termi-
nus of the scFv (myc, his, E-tag). ScFvs can be fused to fluorescence proteins (fluo-
robodies) and used for direct labeling in flow cytometry and immunofluorescence 
microscopy96. These fluorobodies do not fade after illumination compared to (FITC-) 
conjugated antibodies. A new technique called fluorophore-linked immunosorbent 
assay (FLISA) has been developed, in which a scFv is fused to a fluorescent protein 
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and antigen binding is detected by measuring the fluorescence, circumventing the 
need for secondary antibodies. Compared to ELISA, FLISA is a faster and simpler 
method97.
Discussion
After a decade of extensive engineering followed by preclinical and clinical studies, 
antibody fragments partially replaced full IgGs as therapeutic and diagnostic agents. 
Especially when it comes to targeting cancer cells, inflammatory tissue or autoim-
mune and viral diseases, smaller forms of antibodies have ousted full-size IgGs. Re-
cent advances in scaffold design, repertoire construction and selection methods, 
have allowed for the production of specific, high-affinity mAb fragments against 
virtually any target. Owing to the fact that they are simpler to express and can be 
handled in a standard laboratory, truncated structural forms of antibodies play an 
increasingly important role in human health. The creative use of these proteins will 
continue to represent a growing field of protein science, basic and applied biolog-
ical research, and therapeutic discovery. Currently, small fragment antibodies are 
used for the discovery of new cancer biomarkers and are increasingly exploited for 
the development of sensitive microarrays, diagnostic and nanosensor tools. Efforts 
were directed at defining critical parameters for scFv applicability, and their prop-
erties have been altered to provide improved expression, pharmacokinetics and 
in vivo efficacy. Lately, scFvs technology was used as a base for the design of scFv 
multimers, such as diabodies, triabodies, minibodies. Such scFvs derivatives have 
achieved impressive tumor-to-blood ratios and maintain the right balance between 
ideal size and blood clearance as limiting factors. The ability of scFvs to safely deliv-
er toxic chemicals to their targets remains their preferable application in therapy. 
In the form of immunotoxins and nanoparticle–antibody conjugates, scFvs have so 
far shown great potential, and several promising candidates have entered clinical 
trials (Table 1.1). Notably, their primary job is to delivery these cargos selectively to 
diseased cells. The majority of these strategies employ antibody fragments as the 
targeting ligand and delivery platform.
1.5.
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Aim of the thesis
More than 30 years ago, Judah Folkman proposed a revolutionary new idea for a 
novel cancer therapy98. He postulated that, to survive and grow, tumors required 
blood vessels, and that by cutting off blood supply, cancer could be starved into 
remission. The development and use of antiangiogenesis agents, particularly those 
targeting VEGF, have become an integral component of anticancer treatment for 
many tumor types. Since then, a vast spectrum of antiangiogenic inhibitors has been 
developed, and used, either as monotherapy or in combination with other cytotoxic 
and chemotherapy drugs, in clinical trials for the treatment of cancer. Despite ear-
ly success, antiangiogenic therapy was followed by a number of controversies and 
failed to become a reliable option for cancer therapy.
The VEGF/VEGFR-2 axis remains an important and attractive target when targeting 
tumor growth and metastasis. There is a clear need for a new generation of VEGF/
VEGFR-2 inhibitors. Previously, our group and others demonstrated the importance 
of homotypic interactions in the receptor ECD for VEGFR-2 activation. Allosteric reg-
ulatory sites in Domain (D) 4-7 of the VEGFR-2 ECD were identified as attractive 
targets for inhibitory molecules such as DARPins and antibodies99-104. The work pre-
sented in this thesis is focused on targeting the membrane-proximal Ig-homology 
domains 4-7 in the VEGFR-2. Based on our functional analysis of VEGFR-2 activation, 
we aimed at the generation of specific inhibitors binding to D4 and D7 of the ECD, 
which might block receptor activation. We generated four different types of inhibi-
tors. First, we selected scFvs against human VEGFR-2 from the ETH-2 Gold library. 
The best VRGFR-2 inhibitors were fully biophysically characterized and extensively 
tested in in vitro angiogenesis assays. We then reformatted the obtained scFvs into 
larger fragments such as Fabs and IgGs. To identify mouse-specific VEGFR-2 binders 
we used the synthetic ETH-2 Gold library and the R3 EPFL library. In collaboration 
with Molecular Partners AG in Schlieren, our group developed and characterized 
DARPins interacting with the receptor ECD that we further tested for tumor target-
ing in vivo.
Development and in 
vitro application of novel 
VEGFR-2 inhibitory 
single chain fragment 
variable antibodies 
2
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Abstract
Introduction
The role of Vascular endothelial growth factor receptor 2 (VEGFR-2) in tumor an-
giogenesis, growth and metastasis is well appreciated. Unfortunately, available bio-
therapeutics largely failed to show significant improvement in tumor therapy. Here 
we offer allosteric receptor inhibitors as novel inhibitory tools. Instead of competing 
with the ligand for receptor binding, our antibodies block receptor activity by pre-
venting homotypic interaction of extracellular subdomains 4-7 (D4-7) of VEGFR-2, 
previously described to play a role in receptor activation104. To target the VEGFR-2 ex-
tracellular immunoglobulin homology domains D4-7, we isolated novel single chain 
recombinant antibodies, scFvs. ScFvs were obtained from either a synthetic human 
library105 or an antigen-biased immune V-gene phage display library generated from 
murine lymphocytes106. The antibodies were tested for binding to recombinant VEG-
FR-2 extracellular domain protein as well as to live cells expressing the full-length 
receptor. The best binders were biophysically and biologically characterized, in par-
ticular their ability to compete with VEGF binding to VEGFR-2, and their inhibitory 
activity for ligand-mediated VEGFR-2 kinase activation. The antibodies did not block 
VEGF binding to D23, but significantly reduced receptor activity in ligand-stimulated 
VEGFR-2-expressing porcine aortic endothelial cells (PAE KDR). The best inhibitors 
were cloned into a larger format, Fab. Selected binders showed dramatic inhibition of 
VEGFR-2 phosphorylation at Y1175 in a dose-dependent manner and also inhibited 
downstream signaling. Phosphorylation of PLCγ and AKT were inhibited, without an 
effect on total protein levels. In addition, scFvs targeting D4-7 of VEGFR-2 inhibit-
ed VEGF-induced Human Umbilical Vein Endothelial Cells (HUVEC) tube formation 
and migration. Moreover, the cellular mechanism of inhibition was investigated in 
receptor internalization studies. Upon binding of the scFvs, the receptor was rapidly 
cleared from the cell surface, and the internalization was shown to be ligand-inde-
pendent. These findings brought attention to the possibility of using VEGFR-2 scFvs 
as immunotoxin or nanoparticle–antibody conjugates for endothelial cell targeting.
The term angiogenesis comes from the Greek word Angêion, meaning vessel. An-
giogenesis is the process of formation of blood vessels from existing vasculature107. 
It occurs throughout life in both health and disease, beginning in utero and con-
tinuing through old age. Embryonic blood vessels are formed from precursor cells 
(angioblasts) differentiated into endothelial cells that form a  vascular network108. 
Metabolically active tissues are generally located a few hundred micrometers from 
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a blood capillary, formed by the process of angiogenesis. Capillaries are needed in 
all tissues for the exchange of nutrients and oxygen metabolites. Changes in meta-
bolic activity of the tissues are accompanied by proportional changes in capillarity. 
Oxygen plays a critical role in this regulation. VEGFs and their receptors represent 
the key drivers of embryonic vascular development of both physiological and patho-
logical neovascularization109, particularly during rapid tissue growth and metasta-
sis of solid tumors. Tumor cells release VEGF, a mitogen and angiogenesis inducer 
predominantly found in endothelial cells. VEGF is often detected in tumors in situ. 
Early findings indicated that inhibiting the angiogenic factor produced by tumor cells 
might suppress tumor growth in vivo110.
The pioneer of the field of tumor angiogenesis is considered to be Juda Folkman, 
despite the fact that Folkman expanded earlier concepts previously introduced by 
other scientists. In 1939, Ide et al.111 observed that tumor growth was accompanied 
by infiltration of newly formed blood vessels in a rabbit tumor model. Algire112 and 
Chalkeley113 demonstrated that tumors actively promoted new blood vessel forma-
tion in 1945. Finally, the term tumor angiogenesis was coined for the first time 1968 
by Shubi114. Ide, Shubi, Greenblatt, Algire, Chalkeley, Warren111-115 are considered 
to be the founding fathers of the field of tumor angiogenesis, together with Juda 
Folkman98,116,117
The idea of antiangiogenic therapy was pioneered by Judah Folkman in the ear-
ly 1970s. He proposed that by cutting off the blood supply, cancer cells would be 
deprived of nutrients and, consequently, die. Validation of his hypothesis followed 
when bevacizumab, a monoclonal antibody targeting VEGF, was approved as antian-
giogenic therapy in 2004 for the treatment of colon cancer100.
Since then, various strategies that target VEGFR signaling have been developed. No 
satisfactory therapy is available at this time, however. Inhibition of VEGF signaling 
by ligand sequestering agents (bevacizumab)100 or antibodies that block VEGF-VEG-
FR-2 interaction is overcome by high ligand concentration in the tumor, whereas 
the available tyrosine kinase inhibitors are not exclusively specific for VEGFR-2. Here 
we offer a new approach, novel allosteric inhibitors that inhibit VEGFR-2 signaling 
independent of VEGF concentration and relying on a new mechanism of inhibition. 
VEGFR-2 is the most prominent receptor in angiogenic signaling by VEGF ligands. 
The extracellular part (ECD) of VEGF receptors consists of seven immunoglobulin 
homology domains (Ig-domains). The analysis of the role of specific subdomains of 
the VEGFR-2 ECD in receptor activation showed that domains 2 and 3 are required 
for ligand binding118,119, while D4, D5, and D7 are required for stabilizing receptor 
dimers and properly positioning receptor monomers in active dimers102,103. Finally, 
at the functional level we showed that homotypic contacts in D4 and D7 are indis-
pensable for receptor activation104.
To target the VEGFR-2 extracellular Ig domains D4-7, we isolated novel scFvs from 
the ETH-2 Gold library (Figure 2.1). The antibodies were biophysically and biological-
ly characterized. Inhibitory scFvs were reformatted to larger formats such as Fabs 
and IgGs. We determined the biological activity of these antibodies, in particular, 
their ability to compete with VEGF binding to VEGFR-2, and their inhibitory activity 
for ligand-mediated VEGFR-2 kinase activation. The antibodies did not block VEGF 
binding to D23, but did significantly reduce receptor activity and interrupted down-
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stream signaling in a dose-dependent manner. In addition, the series of in vitro an-
giogenesis assays, such as endothelial cell tube formation and migration assays, 
document the therapeutic potential of these antibodies. Moreover, we investigated 
in detail the mechanism of inhibition of these antibodies via receptor internalization, 
trafficking, and signaling studies.
Figure 2.1. Design and cloning strategy of the Philo scFv antibody library. A, B) Three-dimensional structure 
of a scFv antibody fragment, with randomized amino acids, highlighted in circles. In the DP47 heavy chain 
fragment (in red). positions 95–100 were randomly mutated, with the length of the CDR varying from 4 to 7 
amino acids. The antibody in A) shows the DPK22 light chain fragment (in blue). The antibody in B) contains 
a light chain based on the DPL16 germline segment. C) Cloning strategy for the construction of different 
sub-libraries. D) All DNA fragments were amplified, double digested and ligated into the pHEN1 phagemid 
vector. The figure was adapted from120.
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Porcine Aortic Endothelial Cells overexpressing VEGFR2 (PAE KDR) and Human Em-
bryonic Kidney epithelial 293 cells (HEK293) were grown in Dulbecco’s modified 
Eagle’s medium (DMEM; BioConcept, Basel, Switzerland) supplemented with 10% 
fetal bovine serum (FBS) and 1% Penicillin–Streptomycin. Cells were propagated in 
a humidified atmosphere at 37°C and 5% CO2. Human umbilical vein endothelial 
cells (HUVEC), (Lonza) were cultured in EGM-2 medium (Lonza). Cells were grown in 
a humidified atmosphere at 37°C and 5% CO2.
HEK293 cells were grown in standard, previously described conditions until reaching 
60% cell confluency. Transfection with pBE plasmid bearing the full-length VEGFR-2 
sequence was performed with FuGENE (Promega) in Optimem medium (Life Tech-
nologies). 2:3 ratio of DNA:FuGENE was shown to be the most efficient for transient 
cell transfection. Immunostaining was performed 24 hours after transfection. 
PAE KDR cells were serum starved in DMEM supplemented with 1% bovine serum 
albumin (BSA) and stimulated with 1.5 nM VEGF for 10 min at 37°C with or without 
30 min of preincubation with antibody fragments (0.1 to 1 μM). Cell lysates were pre-
pared in lysis buffer (50 mM Tris [pH 7.5], 100 mM NaCl, 0.5% [wt/vol] Triton X-100) 
supplemented with protease inhibitor cocktail (Complete Mini EDTA-free, Roche) and 
phosphatase inhibitors (200 μM Na3VO4, 20 μM phenylarsine oxide).  Lysates were 
diluted in 5x loading buffer (0.25 M Tris-HCl pH 6.8, 0.5 M DTT, 10% SDS, 50% Glycerol, 
0.5% Bromophenol Blue), boiled at 50°C for 30 minutes and resolved by 7% SDS-
PAGE, transferred to PVDF membranes (GE Healthcare), and immunodecorated with 
primary antibodies (dilution 1:1000) followed by secondary alkaline phosphatase-cou-
pled antibodies (1:10000), and developed with Novex AP Chemiluminescent Substrate 
(Invitrogen). Immunoblot assays were analyzed with Amersham Imager 600, GE.
Antibodies used were as follows: pY1175-VEGFR-2 (2478, Cell Signaling), tVEGFR-2 
(2479, Cell Signaling; ab11939, Abacm), pPLCγ1 (2821, Cell Signaling), tPLCγ1 (2822, 
Cell Signaling), pAKT (4060, Cell Signaling), tAKT (4051, Cell Signaling), his-tag (34660, 
Qiagen), myc-tag (2276S, Cell Signaling), anti-rabbit IgG HRP-linked (7074S, Cell Sig-
Materials and methods
Cell culture
Transient transfection
VEGFR-2 kinase activity assay
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naling), anti-mouse IgG HRP-linked (7076S, Cell Signaling); alkaline phosphathase (AP) 
conjugated antibodies were obtained from Jackson ImmunoResearch, fluorescently 
labeled Dylight 488, Cy3 and Cy5 were purchased from Abcam.
Protein marker used for all SDS-PAGE and western blots gels was PageRuler™ Plus 
Prestained Protein Ladder, 10 to 250 kDa (26619, ThermoFisher).
Cells were grown on glass coverslips coated with Poly-L-Lysine (P4707, Sigma) to 
60% confluency. Antibody fragments and VEGF were added to cells in serum starva-
tion conditions. Cells were fixed with 3.7% formaldehyde (FA) in phosphate-buffered 
saline (PBS) for 20 min at 37°C, permeabilized for 10 min with 0.1% NP-40 in PBS 
and blocked for 20 min in 5% BSA in PBS at room temperature (RT). Samples were 
exposed to primary (1:1000) and fluorescently labeled secondary (1:1000) antibod-
ies in PBS containing 5% BSA and embedded in Gelvatol (15% Gelvatol, 33% glycerol, 
0.1% sodium azide). Cells were extensively washed with PBS after each step. Images 
were acquired with an Olympus IX81 equipped with an Andor iXonEM camera and 
with Leica SP5 laser scanning confocal microscope.
The ETH-2 Gold library was kindly provided by Prof. Dario Neri from ETH, Switzer-
land. ETH-2 Gold is a synthetic human antibody library in scFv format. The library has 
been cloned in phagemid vector, encoding for scFv-pIII fused proteins. The ETH-2 
Gold library is based on a single VH segment (DP47) and a single Vk (DPK22) or Vλ 
(DPL16) segment, respectively. These germline variants are dominant in the human 
functional repertoire and represent 12%, 25% and 16% respectively of the antibody 
repertoire in humans. In the ETH-2 Gold library, the flexible polypeptide Gly4Ser-
Gly4SerGly413 was chosen as the linker. ETH-2 Gold scFv antibody fragments were 
cloned into the phagemid vector pHEN121 bearing the short peptidic myc-tag at the 
C-terminus. The ETH-2 Gold library consists of 3 x 109 different antibody clones, and 
it was shown to be highly functional105.
Anti-VEGFR-2 ECD ScFvs were selected from ETH-2 Gold.105. Immunotubes (470319K, 
Nunc) were coated with antigen at a concentration of 10-6 M in PBS overnight at room 
temperature. The following day, the antigen-coated immunotubes were washed 
three times with PBS and blocked with 5% BSA in PBS for 2 hours at room tempera-
ture on the orbital shaker. After the tubes were washed three times with PBS, the 
Immunofluorescence microscopy
ETH-2 Gold library
ScFvs selection
2.3.4.
2.3.5.
2.3.6.
39Dragana Avramović, Doctoral thesis
ScFv A7 used in this study, was obtained from an antigen-biased immune V-gene 
phage display library generated from murine lymphocytes106.
Binders’ specificity was determined by enzyme-linked immunosorbent assay (ELISA) 
using immobilized recombinant VEGFR-2 ECD protein Domain (D) 1 to D7, D1 to D3, 
D1 to D6. Ninety-six-well maxisorp ELISA plates (Nunc) were coated overnight with 
3 g/ml of the target protein. Plates were washed and blocked in PBS/1% BSA/0.1% 
Tween 20. Supernatants from cultured colonies were diluted in blocking solution 
and incubated for 2 h at RT. Plates were washed, and binding was detected using 
myc-tag antibody as primary and HRP-conjugated anti-mouse antibody as second-
phage library (1012-1013 t.u.) was added and incubated for 1.5 h at RT. To remove 
the unbound phage, the tubes were extensively washed with PBS containing 0.1% 
Tween 20 (TPBS) and PBS. Bound phages were eluted with 100 mM Triethylamine 
followed by neutralization with 1M Tris-HCl, pH 7.4. The eluted phage was used for 
the infection of exponentially growing E. coli TG1. Bacterial dilution series were then 
plated on small 2xTY-Amp-Glu agar plates and incubated at 30°C overnight to de-
termine the titer of the eluted phage. The remaining phage-infected bacteria were 
centrifuged for 10 min at 4150 rpm at 4°C. Pelleted cells were resuspended in 0.5 
ml 2xTY, spread on the large 2xTY-Amp-Glu agar plates and incubated at 30°C over-
night. Eluted phages were used to infect exponentially growing E. coli TG1 cells and 
amplified for the next round of selection. After the third round, infected E. coli was 
diluted and plated to obtain single colonies. Single colonies were randomly select-
ed, and the scFvs were tested for binding reactivity with recombinant VEGFR-2 by 
ELISA. Therefore, small-scale bacterial cultures were grown in 96-well plates for 4 h 
at 30°C. The expression of scFv antibody fragments was induced by 1 mM isopropyl 
β-D-thiogalactoside (IPTG), and the cells were grown overnight at 30°C. Following 
centrifugation, supernatants of bacterial cultures containing soluble scFvs were in-
cubated for 1 h at RT in 96-well VEGFR-2-coated (10 μg/ml in PBS) microtiter plates 
and blocked with 5% MPBS. Reactivity of scFvs was detected by anti myc-tag 9E10 
antibody (diluted 1:4000) and horseradish-peroxidase (HRP)-conjugated goat an-
ti-mouse IgG (diluted 1:1000). After extensive washing with TPBS and PBS, the color 
was developed using HRP substrate. Color development was stopped after 20 min 
with 1 M H2SO4 and the absorbance at 450 nm was read using a microplate reader. 
The best binders were identified and used to infect the E. coli non-suppressor strain 
Mach1 for the production of soluble scFv antibodies. The first selection of scFvs 
against human VEGFR-2 was performed by Thomas Schleier.
ScFv A7 
Enzyme-linked immunosorbent assay (ELISA)
2.3.7.
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ary antibodies, followed by peroxidase substrate (ThermoFisher). The reaction was 
quenched by adding 100 μl of 2 M sulphuric acid (H2SO4) to the wells and the OD450 
value for each well was measured with an ELISA reader (TECAN Safire2).
Soluble scFv antibodies were expressed in E. coli Mach1 cultured in 2xYT medium. 
The media containing 100 μg/ml ampicillin and 0.1% glucose was incubated at 37°C 
until bacteria reached an OD600 of 0.8. IPTG was added to a final concentration of 
1 mM to induce expression of antibody fragments. Following a 10-hour incubation 
at 30°C, the bacteria were pelleted by centrifugation at 4000 g for 20 min. The cul-
ture supernatant was filtered through a 0.45 μm filter (Millipore) and purified using 
immobilized metal affinity chromatography (IMAC). Soluble scFv antibodies were 
purified by protein A chromatography (GE) or with Ni-affinity chromatography (GE) 
for scFv A7. Buffers used for Protein A chromatography purification were: binding 
buffer: 20 mM Tris pH 8.0; washing buffer: 20 mM glycine pH 6.0 and elution buffer: 
0.1 M glycine pH 2.5. Affinity chromatography purification was performed with the 
fully-automated liquid chromatography instrument Äkta (GE Healthcare). The flow 
rate was 2 ml/min. Before sample loading, the column was equilibrated with 25 ml 
of binding buffer. Bound scFvs were washed with 60 ml of binding buffer followed 
by a lower pH washing step with 60 ml of washing buffer. The scFvs were eluted 
with 40 ml elution buffer in 2 ml fraction wells containing 100 μl 1 M Tris-base, pH 
8.0. The absorption signal was detected at 280 nm. Fractions containing the protein 
were pooled together and dialyzed overnight against PBS. The next day, the scFvs 
solutions were concentrated and stored at -80°C.
Soluble scFv A7 was purified by Ni-affinity chromatography purification, with the fol-
lowing buffers: binding buffer: 50 mM sodium phosphate, 300 mM NaCl, 10 mM 
imidazole, pH 7.4 and elution buffer: 50 mM sodium phosphate, 300 mM NaCl, 500 
mM imidazole, pH 7.4.
SEC was performed with Superdex S-200 (Amersham Pharmacia Biotech, Switzer-
land) chromatography. The column was equilibrated with 5 column volumes of 
HEPES buffer. The flow rate was 2 ml/min and protein absorption was detected at 
280 nm. 500 µl of the samples were injected onto the column for each run. ScFv A7 
was incubated for 1 h at 4°C with ECD VEGFR-2 at a molar ratio of 2:1.
Expression and purification of scFvs 
Size-exclusion chromatography (SEC)
2.3.9.
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Isothermal titration calorimetry (ITC) was performed at 15°C. The sample cell and 
syringe were filled with 15 μM of scFvs proteins (monomer equivalents) and 400 µM 
of ECD VEGFR2, respectively. Both the protein and the peptides were equilibrated 
in the same buffer (PBS), filtered and degassed before titration. The scFvs (400 μM) 
were loaded in the syringe and were titrated in 2.5 µl injections against 14 µM of the 
protein placed in the sample cell in a MicroCal iTC200 microcalorimeter (Microcal, 
Northampton, UK). Similarly, the control experiments were performed by titrating 
the proteins against buffer. The binding isotherms were fitted by a nonlinear least-
squares minimization method using Origin v8.0 (Microcal Inc., Northampton, MA).
15-well µ-Slides (Ibidi, Germany) were coated with 10 μl of Geltrex® Matrix (Ther-
moFisher) 10 mg/ml and incubated at 37°C for 30 minutes to promote solidification. 
6000 HUVECs were resuspended in growth medium (serum concentration 10%) and 
added to each well with 0.5 - 5 μM inhibitor concentration. After 18 h, the plates were 
fixed with 3.7% formaldehyde (FA). Images were acquired with wide-field fluorescent 
microscope (Olympus IX81 equipped with Andor iXonEM camera). Images were ana-
lyzed using automated image analysis software (http://ibidi.wimasis.com/).
An Agilent 1200 series high-performance liquid chromatography (HPLC) system kept 
in a cold-room was used. The system was equipped with an auto-sampler. A Shodex 
semi-micro KW404-4F (4.6×300 mm) column on the Ettan LC system (GE Healthcare) 
was used for SEC analysis. Running buffer was PBS, pH 7.4 and the column tem-
perature was maintained at 4°C. Samples were ultra-centrifuged at 40000 rpm. The 
settings were the following: FLD1: excitation/emission 435/470 nm, gain 12; FLD2: 
excitation/emission 515/535 nm, detector gain 10. Data was analyzed in OriginLab.
Binding affinity determination by ITC
HUVEC tube formation assay
Fluorescence size-exclusion 
chromatography (FSEC)
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Migration assay was used to assess HUVEC migration (Ibidi, Germany). Cells were 
seeded at 21,000 cells per chamber and allowed to attach overnight. The following 
day, culture inserts were removed and cells were stimulated with 1.5 nM VEGF in the 
presence and the absence of increasing concentrations of scFvs. During the migra-
tion assay, cells were cultured under normal conditions, and images were acquired 
after 8 h. Images were acquired with a wide-field fluorescent microscope (Olympus 
IX81 equipped with Andor iXonEM camera) and analyzed using automated image 
analysis software (http://ibidi.wimasis.com/).
Image analysis was performed using the ImageJ plugin Squassh122. Squassh com-
bines segmentation and deconvolution in a single step, yielding better results for 
small objects close to the diffraction limit of the microscope. Squassh was used to 
segment intracellular vesicles and cells. Squassh Analyst was used for data analysis 
and normalization of the vesicle count relative to cell area 123.
For statistical analysis of experimental data, multiple comparisons were investigated 
for significant differences by 1-and 2-way ANOVA. Individual comparisons were subse-
quently performed by using the Bonferroni post-test or unpaired Student’s t-test, as 
Protection of VEGFR-2 from extracellular trypsin treatment was exploited in quanti-
fication of the internalized VEGFR-2. Following treatment in conditioned media, PAE 
KDR cells were washed three times with ice cold PBS and then incubated on ice 
with freshly prepared trypsin (1 mg/mL, Sigma) for 30 minutes. Reactions were then 
quenched by the addition of soy bean trypsin inhibitor (50 mg/mL, Sigma). Cells 
were collected very gently with soft scrapers into tubes for centrifugation at 500 rcf, 
4°C for 5 minutes. The PBS was aspirated and the pellet suspended in a small vol-
ume of ice-cold PBS; the cells were then lysed by the addition of the sample buffer 
for gel electrophoresis. Lysates were boiled at 95°C and analyzed by Western blot.
HUVEC migration assay
Squassh analysis of VEGFR-2 internalization
Statistical analysis 
Trypsin digestion of cell surface exposed 
receptor
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appropriate. Unless otherwise stated, experiments were performed in triplicate. Data 
is expressed as mean ± SD, where n is the number of individual experiments; p val-
ues ≤0.05 were considered statistically significant in two-sided tests. Unless otherwise 
stated, all numerical and graphical analyses were performed in Microsoft Office Excel 
2010 (Microsoft, USA) and GraphPad Prism version 7.0 (GraphPad Software, USA).
ScFvs specific for human VEGFR-2 were generated with the ETH-2 Gold phage li-
brary105 (Figure 2.2, A, B). After three rounds of selection, positive clones were cho-
sen at random for further analysis. Selected clones were tested for specificity for 
VEGFR-2 by ELISA. Binders with the highest ELISA signal were sequenced and scFvs 
with unique sequences were selected for further analysis (Figure 2.2, C). The large-
scale expression of scFvs was performed in Mach-1 E. coli and soluble scFv anti-
bodies were purified from the filtered culture supernatant with Ni-affinity chroma-
tography and protein A chromatography. ScFv antibodies were expressed in E. coli 
Mach1. The bacteria were cultured in 2xYT medium containing 100 μg/ml ampicillin 
and 0.1% glucose at 37°C until they reached an OD600 of 0.8 IPTG was added to a 
final concentration of 1 mM to induce expression of scFv antibodies. Following 10 
hours incubation at 30°C, the bacteria were pelleted by centrifugation at 4000 g for 
20 min. Soluble scFv antibodies were purified from the filtered culture supernatant 
by Ni-affinity chromatography (GE) (Figure 2.3, A) and protein A chromatography 
(GE) (Figure 2.3, C). The eluted peak fractions were loaded on 12% polyacrylamide 
gel and analyzed by Coomassie blue staining (Figure 2.3, B, D). The obtained yield of 
scFvs was in the range of 1 – 4 mg from 1 l of bacterial culture.
Results
Selection, production, and purification of 
scFvs antibodies
2.4.
2.4.1.
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Figure 2.2.The amino acid sequences of the scFvs. A) Schematic of scFvs amino acid sequences from ETH-2 
Gold library used for selection105 B) Full amino acid sequences of scFvs selected against human VEGFR-2 
where randomized CDR3 was represented with letters K in red C) Randomized CDR3 amino acid sequence 
of scFvs selected against human VEGFR-2.
V H 
A E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S S Y A M S W V R Q A P G K G 
L E W V S A I S G S G G S T Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D 
T A V Y Y C A K K K K K  F D Y W G Q G T L V T V S S  
V L 
S S E L T Q D P A V S V A L G Q T V R I T C Q G D S L R S Y Y A S W Y Q Q K P G Q A P V L V 
I Y G K N N R P S G I P D R F S G S S S G N T A S L T I T G A Q A E D E A D Y Y C N S S K K K 
K K K  V V F G G G T K L T V L G  
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Figure 2.3. ScFvs purification by protein A and Ni-affinity chromatography. A) Elution profile of scFv A7 after 
purification by Ni-affinity chromatography. B) The eluted peak fractions loaded on 12% polyacrylamide gel 
and analyzed with a Coomassie blue staining. C) Elution profile of scFv G3 after purification by protein A. 
D) The eluted peak fraction loaded on 12% polyacrylamide gel and analyzed by Coomassie blue staining.
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Figure 2.4. Determining domain specificity of selected scFvs by ELISA. A) ELISA results show VEGFR-2 domain 
specificity by measuring absorbance at 450 nm. ELISA was performed with different length VEGFR-2 ECDs. 
B) Overview of scFvs domain specificity. C) Determining domain specificity of scFv A7 by size-exclusion chro-
matography (SEC) of scFv A7 in complex with different length VEGFR-2 ECDs. Proteins from collected peak 
fractions were concentrated and resolved on 12% SDS-PAGE gel.
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Figure 2.5. ScFvs binding to recombinant VEGFR-2 in FSEC. FSEC analysis shows scFvs binding to both VEG-
FR-2 ECD and VEGFR-2 ECD/VEGF complex. The shift in the peak to the left (from red to blue peak) demon-
strates the formation of new larger species in the combination of VEGFR-2 ECD and scFvs (top panel) and 
VEGFR-2 ECD/VEGF and scFvs (bottom panel).
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Binder specificity was confirmed with ELISA on human VEGFR-2 (hVEGFR-2) and 
mouse VEGFR-2 (mVEGFR-2) (Figure 2.4, A, B). The positive signal was detected at 
the OD450. All presented antibodies were specific for hVEGFR-2, but were not binding 
mVEGFR-2. The binding specificity for scFv A7 was determined by SEC where scFv 
A7 was incubated with ECD VEGFR-2 at a 2:1 molar ratio for 1 h at 4°C and conse-
quently loaded on a Superdex S-200 (Amersham Pharmacia Biotech, Switzerland). 
Collected peak fractions were concentrated and resolved on 12% SDS-PAGE gel 
(Figure 2.4, C). Purified scFv A7 was loaded in the last well to serve as a size control. 
ScFv A7 forms complexes in combination with full-length ECD (D1-7), D1-6 and D1-3, 
which means that it binds VEGFR-2 ECD D1-3. SDS-PAGE shows all protein species 
collected as a single peak, including a 30 kDa protein, which is the size of scFv A7. 
Larger protein species are D1-7, D1-6 and D-3 respectively. Multiple bands visible on 
the gel are degradation products. 
FSEC (Figure 2.5) on hVEGFR-2 (top panels) and on hVEGFR-2 VEGF complex (bottom 
panels) show a shift of the peak to the left (from red to blue peak), meaning that a 
larger protein species was formed. This demonstrates that scFvs bind both VEGFR-2 
ECD and VEGFR-2 ECD VEGF complex, confirming that scFvs and VEGF have different 
VEGFR-2 binding sites. Live cells binding was confirmed in HEK293 cells by immu-
nostaining. First, VEGFR-2/Dylight 488 staining was used to confirm VEGFR-2 expres-
sion on the cell surface (green); subsequently, myc-tag/Cy3 (red) staining showed 
that scFvs bind the receptor on the surface of transiently transfected HEK293/VEG-
FR-2 cells (Figure 2.6). Affinities of the scFvs were determined by ITC (Figure 2.7, A). 
The calculated Kd values are shown in the Table (Figure 2.7, B).
Binding of scFvs to recombinant and 
endogenous VEGFR-2.
Figure 2.6. ScFvs binding to VEGFR-2 expressed on HEK293 cells. Green signal (top panel) represents VEG-
FR-2 immunostaining with Abcam antibody (11939). Red signal demonstrated scFvs binding to HEK cells 
transfected with VEGFR-2 (bottom panel). Non-transfected HEK293 control (left, middle panel) shows the 
background signal. 
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Activation of VEGFR-2 is a key step in angiogenesis. We, therefore, investigated the 
potential of scFvs to inhibit this process by blocking VEGFR-2 signaling in vitro. We ex-
posed PAE KDR cells to various concentrations of scFvs in the presence or absence 
of VEGF. Analysis revealed that increasing concentrations inhibited kinase phos-
phorylation at Y1175 in a dose-dependent manner. VEGFR-2 was phosphorylated by 
the addition of exogenous VEGF to PAE KDR cells (Figure 2.8). Pretreatment of cells 
with increasing concentrations of scFvs in the presence of VEGF showed inhibition 
of Y1175 phosphorylation in a dose-dependent manner, without affecting overall 
VEGFR-2 expression levels. In order to identify the effects of scFvs on downstream 
signaling, we examined the expression and phosphorylation of PLCγ, AKT, and p38. 
While PLCγ signaling was clearly inhibited, AKT signaling did not show statistically 
significant change. The challenges in quantifying phospho-AKT are the consequence 
of the small difference between basal and fully activated pospho-AKT levels. While 
treatment of PAE KDRs with antibodies inhibited VEGF-dependent phosphorylation 
of downstream signaling in a dose-dependent manner, total protein levels were un-
affected (Figure 2.8, A). All kinase assays were performed in triplicates and quantified 
with ImageJ software. Quantified data was analyzed with GraphPad (Figure 2.8, B).  
Functional inhibition of VEGFR-2 
phosphorylation with scFvs
Figure 2.7. Thermodynamic analysis of antibody-VEGFR-2 interaction. A) ITC analysis of scFvs in complex 
with VEGFR-2 ECD. Raw data and binding isotherms are shown. B) Calculated thermodynamic parameters of 
interactions are summarized in the Table.
2.4.3.
Complex Stoichiometric Coefficient, N Kd (nM) ΔH (kcal mol-1) TΔS (kcal mol-1)
ECD + scFv A7 0.839 92.6 -4383 17
ECD + scFv G3 1.21 137 -7936 3.85
ECD + scFv F1 1.38 6800 -7283 -1.63
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Figure 2.8. Effect of antibody treatment on VEGF-induced signaling in PAE KDR cells. A) scFvs inhibit phos-
phorylation of Y1175-VEGFR-2, PLCγ and AKT in a dose-dependent manner. B) The western blot data was 
analyzed and quantified with ImageJ. Quantification of western blot data shown as n-fold increase over the 
activity of ligand-induced receptor activity in the absence of scFv antibodies. Data distribution and statistical 
analysis were performed using GraphPad, Prism 7. It demonstrates a representative experiment of four 
independent experiments. Error bars represent ± Standard Deviation (SD). The statistical significance based 
on a Student’s t-test is indicated by * representing P<0.05.
We examined the role of our antibodies in the formation of capillary-like tubes 
formed by endothelial cells in Matrigel. HUVEC cells were embedded in Matrigel and 
treated for 8 h with VEGF in the presence or absence of increasing concentrations 
of scFvs. After the incubation period, the formation of tubes was examined by phase 
contrast microscopy. Results show that VEGF triggers the formation of a dense net-
work of tubule-like structures when added to control HUVEC in Matrigel. This effect 
was markedly repressed in cells to which scFvs were added (Figure 2.9, A).  Four 
independent experiments were performed for each concentration of scFvs and an-
Effect of antibodies on HUVEC tube 
formation and migration.
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Figure 2.9. Effect of antibody treatment on VEGF-induced capillary-like tube formation in HUVECs. A) Light 
microscopy of capillary-like tubes formed in the presence and absence of increasing concentrations of an-
tibodies. The total tube length was quantified with Wimasis online software (http://ibidi.wimasis.com/). B) 
Quantification of data shown as n-fold increase over the activity of ligand-induced tube formation in the 
absence of scFv antibodies. Data distribution and statistical analysis were performed using GraphPad, Prism 
7. It shows the results of a representative experiment, out of four independent experiments. Error bars 
represent ± SD. The statistical significance based on a Student’s t-test is indicated by * representing P<0.05.
alyzed with Wimasis online software (http://ibidi.wimasis.com/). Data was quantified 
with GraphPad (Figure 2.9, B). 
The migration and invasion of endothelial cells are critical features in the formation 
of new blood vessels and in the repair of injured vessels. Therefore, we investigat-
ed the effects of scFvs on the movement of HUVECs from a wounded edge to an 
open area using wounding migration assays (Figure 2.10). Treatment with scFvs de-
creased the migration of HUVECs compared to that of control in a dose-dependent 
manner (Figure 2.10, B).
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Figure 2.10. Effect of antibody treatment on VEGF-induced wound healing assay in HUVECs. A) Time course 
of VEGF-induced cell migration. B) Growth curve of HUVEC cells. C) Cells migrating in presence and ab-
sence of increasing concentrations of antibodies. D) Quantification of data shown as n-fold increase over 
the activity of cell migration in the absence of scFv antibodies. Data distribution and statistical analysis 
were performed using GraphPad, Prism 7. It shows a representative experiment out of three independent 
experiments. Error bars represent ± SD. The statistical significance based on a Student’s t-test is indicated 
by * representing P<0.05.
VE
GF
0
A7
0.5 µM scFv + VEGF  1 µM scFv + VEGF 5 µM scFv + VEGF VEGF
G3
F1
2 h 4 h 12 h
80
Ce
ll 
nu
m
be
r
60
0.5
 μM
 sc
Fv
 A7Cn
trl
1 μ
M 
sc
Fv
 A7
0.5
 μM
 sc
Fv
 G
3
5 μ
M 
sc
Fv
 A7
1 μ
M 
sc
Fv
 G
3
5 μ
M 
sc
Fv
 G
3
0.5
 μM
 sc
Fv
 F1
1 μ
M 
sc
Fv
 F1
5 μ
M 
sc
Fv
 F1
40
20
0
* * * * * *
D)
Ce
ll 
nu
m
be
r
Time (h)
100
50
0
0 2 4 12
150
B)A)
C)
53Dragana Avramović, Doctoral thesis
Two approaches were used to determine receptor internalization. Firstly, immu-
nostained VEGFR-2 was used to follow the time-dependent increase of intracellular 
vesicles and vesicle volume upon VEGF or scFv addition (Figure 2.11, A). Individual 
incubation, not only with VEGF but also with scFv alone led to a dramatic increase 
of both critical parameters. When both scFv and VEGF were present at the same 
time, we could observe an additive effect on total vesicle volume after 10 minutes, 
which suggests that a similar mechanism of internalization is involved in both VEGF 
and scFv mediated internalization. To quantify the observed phenomenon, we used 
Squassh software and analyzed 25 images per condition (Figure 2.11, B). 
To confirm that VEGFR-2 is indeed internalized upon scFvs binding, a simple method 
that distinguishes between internalized and cell surface proteins was used. Trypsin 
was used for proteolysis of membrane-bound extracellular proteins. Upon incuba-
tion with trypsin cell surface proteins are cleaved, including VEGFR-2, while the in-
ternalized proteins are protected from the extracellular trypsin and remain intact. 
The cell lysis was followed by Western blot analysis (Figure 2.11, C). Two time points 
were assessed. A basal level of internalization was detected in the absence of both 
scFvs and VEGF (blue arrow). However, the most pronounced band was the lower 
band (red arrow) representing the product of receptor degradation. Incubation with 
scFv C11, non-inhibitory control led to the same outcome. In the presence of VEGF, 
VEGFR-2 is quickly internalized and protected from trypsin degradation, therefore 
only the band that corresponds to the size of intact VEGFR-2 (blue arrow) can be 
observed. When incubating with inhibitory scFvs only, both the trypsin digestion 
product and a more pronounced intact VEGFR-2-sized band can be observed. Inter-
estingly, 45 minutes incubation with scFv A7 yielded the same outcome as incuba-
tion with VEGF, demonstrating that scFv A7 leads to slower but complete VEGFR-2 
internalization. Incubation with scFv G3 did not lead to a complete internalization 
after 45 minutes, which can be explained by the higher affinity of scFv A7 compared 
to scFv G3 (Figure 2.7, B). However, at the same time, this is in line with the better 
inhibitory effect of scFv A7 in kinase assay (Figure 2.8) and Tube formation assay 
(Figure 2.9). The trypsin degradation assay thus confirmed the immunostaining data, 
indicating that both VEGF and scFv led to receptor internalization.
VEGF and scFvs induce internalization of 
VEGFR-2
2.4.5.
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Figure 2.11. VEGFR-2 internalization study. A) Immunostaining of VEGFR-2 receptor with Abcam antibody 
(ab11939) shows the receptor dynamics upon scFv G3 or VEGF binding, or a combination of both. PAE KDR 
cells were fixed at different time points after addition of scFv G3, VEGF or scFv + VEGF. Vesicle number/
volume was analyzed upon VEGF or/and scFv binding. B) Squassh analysis of immunostaining data was 
performed122. Data distribution and statistical analysis were performed using GraphPad, Prism 7. It shows 
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a representative experiment out of 25 independent experiments. Error bars represent ± SD. The statistical 
significance based on a Student’s t-test is indicated by * representing P<0.05. C) Trypsin degradation profile 
of VEGFR-2 upon scFvs or/and VEGF binding. 
Several antiangiogenic inhibitors have been developed and used in clinical trials for 
the treatment of cancer, either as monotherapy or in combination with other cyto-
toxic and chemotherapy drugs. Despite an early success, antiangiogenic therapy 
was plagued by a number of controversies and failed to become a viable option for 
cancer therapy.
The VEGF/VEGFR-2 axis remains an important and attractive target when targeting 
tumor growth and metastasis. There is a clear need for a new generation of VEGF/
VEGFR-2 inhibitors. Our group and other researchers have previously demonstrat-
ed the importance of homotypic interactions in the receptor ECD for VEGFR-2 ac-
tivation. Allosteric regulatory sites in D4-7 of VEGFR-2 were identified as an attrac-
tive target for inhibitory molecules such as DARPins and antibodies99-104. VEGFR-2 
specific antibody fragments were therefore produced as a potential therapeutic 
tool. Selected scFvs showed species-specificity by binding to both purified human 
receptor and HEK293 cells transiently expressing hVEGFR-2 on the surface. The 
affinity of scFvs differed significantly depending on scFv variant. The best binders 
demonstrated affinity in the nanomolar range. The Kd values of here presented 
inhibitors were in the range reported for several therapeutic antibodies124. Selected 
antibodies showed consistent inhibition of different aspects of VEGF-driven angio-
genesis in a number of in vitro assays. ScFvs fully suppressed VEGF-induced VEGFR-2 
phosphorylation and downstream signaling. Inhibitory potential of scFvs was further 
demonstrated in HUVEC tube formation and wound healing migration assays, where 
VEGF-dependent proprieties of HUVECs including the formation of capillary-like 
tubes, demonstrating vessel formation, as well as migration from a wounded edge 
to an open area, demonstrating wound healing, were inhibited. Most interestingly, 
internalization studies revealed a possible cellular mechanism of inhibition. Anti-
body fragments binding to VEGFR-2 led to receptor internalization as demonstrated 
by an increase in total volume of intracellular receptor-positive vesicles. Internaliza-
tion independent of ligand binding represents a new promising property of these 
VEGFR-2 antibodies. Drebin et al.125 and Hudziak126 et al. have demonstrated that 
anti-HER2 MAbs reduce the amount of HER2 protein expressed on the cell surface. 
The mechanism by which anti-HER2 MAbs induce HER2 downregulation is unclear, 
although it is shared by other anti-growth factor receptor antibodies such as anti- 
EGFR127 antibodies. The indication is that the antibodies synthesized in this study 
share some propriety with the well characterized anti-HER2 MAbs. It still remains 
to be determined why scFvs lead to VEGFR-2 internalization. Two possible explana-
tions are offered herein. One possible reason may be antibody-induced receptor 
clustering: clustering of scFv-VEGFR-2 complexes could cause efficient internaliza-
tion. Similar effects have been described for Pertuzumab-HER2128,129. The second ex-
Discussion
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planation could lay in allosteric properties of scFvs. By binding VEGFR-2, scFvs could 
be causing structural alteration of the receptor which cells recognize as improperly 
folded receptors that need to be internalized and recycled or degraded.
The ability of scFvs to selectively and safely deliver a cocktail of toxic chemicals to 
the target cell remains their preferable application in therapy. Due to the demon-
strated receptor internalization propriety, these antibodies might be useful as im-
munotoxin or nanoparticle–antibody conjugates with the potential to deliver ther-
apeutic cargos to diseased cells. Such a strategy would employ antibody fragments 
as the targeting ligands.
Here, antibody fragments have been described as an attractive alternative to inhibit 
the VEGF/VEGFR-2 activation. Currently available antiangiogenic strategies, ligand 
sequestering antibodies, small molecular weight tyrosine kinase inhibitors (TKIs), 
and VEGFR ligand blocking antibodies, are affected by high local VEGF concentra-
tions. Compared to available therapeutics, the antibodies presented herein might 
even function at high ligand concentrations. It is believed that free ECDs regulate 
the local VEGF excess. By neutralizing the ligand, the fine balance between free and 
bound VEGF is disrupted and may consequently lead to aberrant signaling. In addi-
tion, VEGFR-2 forms dimers with VEGFR-1 and VEGFR-3130. The activity of VEGFR-1 as 
a kinase is low, but in heterodimeric form with VEGFR-2, VEGFR-1  participates in an-
giogenic signaling131,132. VEGFR-2/VEGFR-3 heterodimers are described to play a role 
in full VEGFR-3 activation133. We believe that a similar mode of action, requiring D4-7 
interactions as described for VEGFR-2 homodimers is present in heterodimers. Al-
though no heterodimer structure was yet solved, the hypothesis is that interactions 
in domains 4-7 are necessary to position all members of the VEGF receptor family 
in an active conformation in the ligand binding dimer. It would seem reasonable to 
assume that the antibodies presented herein, targeting these interactions in both 
homodimeric and heterodimeric receptor complexes could represent promising 
new tools for antiangiogenic therapy. 
In summary, a series of novel antibody fragments with a new mode of action to 
target VEGFR-2 mediated signaling has been described and it has been shown that 
allosteric inhibition of VEGFR-2 is an effective mechanism for inhibiting VEGFR-medi-
ated effects in several tissue culture models. The next step would be to apply these 
new tools in animal models such matrigel implant assays in mice. 
Also, it would be interesting to further examine scFvs-induced VEGFR-2 internaliza-
tion. What is the exact mechanism of internalization? To which cellular compartment 
does receptor go upon internalization?  What happens with scFvs when VEGFR-2 is 
internalized? What is the ultimate destiny of the internalized receptor? Is it recycled 
or degraded? All these questions remain to be answered.
Reformatting scFv 
antibodies to Fragment 
Antigen Binding (Fab) 
antibody fragments
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Recombinant antibodies, including antibody fragments, have become a fundamen-
tal tool in medical research and therapy134-139. In the previous chapter, we discussed 
scFv antibodies in detail, with the focus on advantageous properties such as smaller 
molecular sizes, easy production, higher penetrability and elimination of the Fc region 
when compared to the full-length IgGs. Therefore, smaller particles penetrate tumors 
more rapidly and uniformly than larger particles140, and smaller particles carrying 
drugs are more effective against tumors than larger particles141. On the other hand, 
smaller particles are eliminated more quickly from the blood142. The choice of nano-
medicine drug size for a cancer type involves finding a balance between maximizing 
tumor penetration and minimizing both toxicity to normal tissue and blood clearance.
Both scFv and Fab formats share the above-mentioned advantages. However, the 
Fab format appears to be more stable143 and to have considerably slower blood 
clearance when compared to the scFv format142. In some reports reformatting scFv 
to Fab lead not only to improved stability but to improved neutralization activity as 
well144. Preserving the properties of the small antibody fragments and at the same 
time, improving blood clearance, Fab format proved to be the preferential tool for 
tumor and tissue imaging145. In order to obtain a Fab and to compare its properties 
with scFv format, we used the best VEGFR-2 inhibitory scFvs previously selected and 
characterized (Chapter 2).
To transfer the heavy chain variable domain (VH) and light chain variable domain (VL) 
from pHEN to pEA and pMX9 vectors already bearing heavy chain constant domain 
CH and light chain constant domain (CL) respectively, VH and VL were PCR amplified 
by using the following primers: 
SMM17 scH9_VH-SapF 5’-atatatGCTCTTCtAGTgaggtgcagctggtggagtctg-3’; 
SMM18scH9_VH-SapR 5’-tatataGCTCTTCaTGCTCTCGACACGGTGACCAGG-
GTT-3’ for VH and
SMM15 scH9_VL-SapF 5’-atatatGCTCTTCtAGTtctgagctgactcaggaccctg-3’; 
SMM16 scH9_VL-SapR 5’-tatataGCTCTTCaTGCGCCTAGGACGGTCAGCTTG-
GTC-3’ for VL PCR amplification.
Introduction
Materials and methods
Cloning strategy for reformatting scFvs to 
Fabs 
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Amplified DNA was gel-purified and assembled. The assembly was performed in two 
steps. Firstly, VH and VL were ligated in pEA and pMX9 vectors respectively by using 
SapI (New England Biolabs); secondly, heavy chain (VH + CH) was digested with SfiI 
(New England Biolabs) and ligated into pMX9 already bearing the light chain (VL + CL). 
The obtained DNA was sequenced with sequencing primers:
SMM25 primer (pMX9_ompAseq for VH): 5’-AAGACAGCTATCGCGATTG-3` 
and 
SM03 primer (pMX9_ompAseq for VL): 5’-ATGTTGTGTGGAATTGTGAGCGG-3`
Each pMX9 vector containing the corresponding Fab was electro-transformed into 
Mach1 E. coli competent cells. The cells were cultured in Terrific Broth (TB) medium 
supplemented with 0.1% glucose plus chloramphenicol (17 µg/ml) at 37°C and in-
duced with 1 mM IPTG when the culture reached an OD600 = 0.8. After induction, the 
culture was grown at 30°C for 12 h, centrifuged at 6000 rpm at 4°C for 15 min and 
the pellet was resuspended in the lysis buffer containing 50 mM Tris pH 7.5, 150 
mM NaCl, with the addition of 1 mg/ml lysozyme, 20 μg/ml DNase and 2 complete 
protease inhibitor tablets. The cells were homogenized with Turrax disperser (IKA) 
and lysed by high-pressure Emulsi-Flex C-3 (Avestin®) at 15000 psi. Unlysed cells, 
cell debris, and aggregates were removed by centrifugation at 17000 rpm for 45 
minutes. Fabs were purified from the filtered supernatant by Ni-affinity chromatog-
raphy, equilibrated with 5 ml of binding buffer: 50 mM Tris pH 7.5, 150 mM NaCl, 10 
mM imidazole. Samples were eluted with elution buffer: 50 mM Tris pH 7.5, 150 mM 
NaCl, 500 mM imidazole. Eluted fractions, containing the Fabs were collected and 
used immediately for analysis or stored at -80°C.
To confirm that obtained Fabs preserved the same inhibitory properties as scFvs, 
kinase activity assay and HUVEC tube formation assay were performed as previously 
described in chapter 2.
Expression and purification of soluble 
Fabs
Receptor kinase activity assay and HUVEC 
tube formation assay
3.2.2.
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The scFvs described in the previous chapter to inhibit VEGFR-2 phosphorylation 
were now transformed into Fabs, and their specificity, affinity and inhibiting capacity 
were assayed. Gel-purified DNA fragments encoding the variable domains of the 
light and heavy chains of the corresponding scFv were amplified by PCR (Figure 3.1). 
VL and VH were cloned into two distinct plasmids (pMX9 and pEA, respectively). The 
assembly was performed using SapI. Final ligation of heavy chain (VH + CH) into pMX9 
bearing light chain (VL + CL) was performed with SfiI (Figure 3.1). The DNAs were se-
quenced with sequencing primers SMM26 and SM03.
The Fabs sub-cloned into pMX9 vector were expressed by IPTG induction using the 
Mach1 E. coli strain. The recombinant Fabs were extracted from the periplasm and 
purified by Ni-affinity chromatography (Figure 3.2, A). The typical yield was around 1 
mg of soluble protein per liter of culture. The Fab fractions under SDS-PAGE condi-
tions showed a MW of approximately 50 kDa (Figure 3.2, B). 
ITC was performed for Fab F1 as previously described for scFvs. Kd values for Fab 
F1 showed approximately 10-fold increased activity when compared with Kd values 
for scFv F1. (Figure 3.3). 
Results
Construction of Fab format
Expression and purification of Fabs
Affinity determination with ITC
3.3.
3.3.1.
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Figure 3.1. Construction of Fabs. DNA fragments encoding the variable domains of the light and heavy chains 
of the corresponding scFv, were amplified by PCR and cloned into two distinct plasmids (pMX9 and pEA, 
respectively), which contained the human CL or CH constant domains by digestion with SapI. Heavy variable 
fragment, previously cloned into pEA, was subcloned into pMX9 vector containing the light Fd fragment by 
digestion with SfiI, resulting in pMX9Fab vector. 
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Figure 3.2. Fab purification by protein Ni-affinity chromatography. A) Elution profile of Fab F1 after purifica-
tion by Ni-affinity chromatography shows two peaks in washing step and in elution step. B) The eluted peak 
fractions loaded on 12% polyacrylamide gel and analyzed with a Coomassie blue staining. 
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Figure 3.3. Comparison of thermodynamic analysis of antibody-VEGFR-2 interactions. A) ITC analysis and 
of scFv F1 and corresponding Fab F1 in complex with VEGFR-2 ECD. Raw data and binding isotherms are 
shown. B) Calculated thermodynamic parameters of interactions are summarized in the Table. 
Both assays were performed as previously described for scFvs in chapter 2. Analysis 
of the kinase assay revealed that increasing concentrations of Fabs inhibited kinase 
phosphorylation at Y1175 in a dose-dependent manner. VEGFR-2 was phosphory-
lated by the addition of exogenous VEGF to PAE KDR cells (Figure 3.4). Pretreatment 
of cells with increasing concentrations of scFvs in the presence of VEGF showed 
inhibition of Y1175 phosphorylation in a dose-dependent manner, without affecting 
overall VEGFR-2 expression levels. To identify the effect to downstream signaling by 
Fabs, the expressions and phosphorylation of PLCγ, AKT, and p38 were examined. 
PLCγ signaling was clearly inhibited, whereas p38 and AKT signaling did not show a 
statistically significant change. While treatment of PAE KDRs with antibodies inhibit-
Receptor kinase activity assay and HUVEC 
tube formation assay
3.3.4.
Complex Stoichiometric Coefficient, N Kd (nM) ΔH (kcal mol-1) TΔS (kcal mol-1)
ECD + scFv F1 1.38 6800 -7283 -1.63
ECD + Fab F1 0.754 869 -6075 6.64
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Figure 3.4. Effect of antibody treatment on VEGF-induced signaling in PAE KDR cells. A) Fabs inhibit phosphor-
ylation of Y1175-VEGFR-2, PLCγ and AKT in a dose-dependent manner. The western blot data was analyzed 
and quantified with Image J. B) Quantification of data shown as n-fold increase over VEGF-induced signaling 
in the absence of Fabs antibodies. Data distribution and statistical analysis were performed using GraphPad, 
Prism 7. A representative experiment, out of three independent experiments, is shown. Error bars represent 
± SD. The statistical significance based on a Student’s t-test is indicated by * representing P<0.05. 
ed VEGF-dependent phosphorylation of downstream signaling in a dose-dependent 
manner, total protein levels were unaffected (Figure 3.4, A). All kinase assays were 
performed in triplicates and quantified with ImageJ software. Quantified data was 
analyzed with GraphPad (Figure 3.4, B). For Fab H5 we observed a high standard 
deviation at 0.1µM concentration which can be explained by having one quantified 
point with considerably different value compared to others in triplicates. 
HUVEC tube formation assay shows that VEGF triggers the formation of a dense 
network of tubule-like structures. Added Fab F1 repressed this effect (Figure 3.5, 
A). Four independent experiments were performed for each concentration and the 
tube-like structures were analyzed with ImageJ software. Data was quantified with 
GraphPad (Figure 3.5, B).
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Figure 3.5. Effect of antibody treatment on VEGF-induced capillary-like tube formation in HUVECs. A) Light 
microscopy of capillary-like tubes formed in the presence and absence of increasing concentrations of 
Fab antibody. 
To provide the best VEGFR-2 imaging tool for in vivo studies, some of the previously 
synthesized scFvs were reformatted to Fabs. A method for the production of Fabs 
from preselected scFvs from ETH-2 Gold library previously developed by Prof. Dr. 
Raimund Dutzler’s group from the University of Zürich was tested. VH or VL domains 
were PCR amplified and cloned into a single bacterial pMX9 vector. Fabs were func-
tionally expressed in Mach-1 E. coli. Fabs maintained domain specificity. The affinity 
of the Fab F1 was compared to that of corresponding scFv F1, and we observed 10-
fold increase in affinity. This can be explained by the findings that Fabs are generally 
more stable compared to the scFv format144. Since ITC data for other scFv/Fab pairs 
is not available, it is impossible to determine whether the increase of affinity for 
reformatted scFv F1 to Fab F1 is a single event or is consistent for all the observed 
Fabs. The Fabs preserved inhibitory activity previously demonstrated for scFvs in the 
kinase activity assay in PAE KDR cells and in the HUVEC tube formation assay. Future 
experiments could, therefore, consist of further characterization of the obtained 
Fabs, including the determination of missing affinities against D1-7 by Isothermal 
Titration Calorimetry. The Fabs may further be tested for inhibition of HUVEC migra-
tion discussed in section 3.5 for the scFvs and in in vivo imaging experiments.
Discussion
3.4.
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Obtaining full-length 
IgGs from previously 
characterized VEGFR-2 
inhibitory scFvs
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Despite the wealth of available antibody formats, immunoglobulin G (IgG) remains the 
most accepted therapeutic antibody format2, whereas small recombinant antibod-
ies18,21,40,41 are required for in vitro antibody generation and engineering during drug 
development. Single chain antibody fragments such as scFvs or Fabs are especially well 
suited for phage display and bacterial expression20,40. One of the major drawbacks of the 
scFv format is its reduced affinity compared to the full-length IgG. In general antibody 
affinity of 1 nM or less is required for clinical application; thus, one or several cycles of 
affinity maturation are important steps during antibody generation44,146. Conversion of 
in vitro optimized antibody fragments back to IgGs will result in similar or improved an-
tigen binding affinity147. Surprisingly, some studies have demonstrated a loss of affinity 
after reformatting scFv fragments into IgGs148, which can partially diminish the benefit 
from affinity maturation in the scFv format149. Increasing efforts are being made to ad-
dress the challenges related to IgG reformatting from small antibody fragments, such as 
screening of vast numbers of scFv clones, full batch conversion into the IgG format after 
selection in combination with mammalian expression system for screening150 or Fab 
display on yeast47. Changing the expression host during screening may overcome re-
strictions of the E. coli expression system. However, this requires more time and effort, 
and also introduces a risk of error in the additional subcloning steps. For the purpos-
es of this study, two different strategies were tested for the conversion of anti-human 
VEGFR-2 scFvs into full IgGs, so that they could be used in animal angiogenesis models.
Introduction
The method used for reformatting with the pcDNA3 vector was previously developed 
and described by Grünberg at al. 2003151. To obtain IgG formats, the DNA of heavy 
chain (VH) and light chain (VL) variable regions from scFvs were PCR amplified. Purified 
DNA was subcloned into two separate pcDNA3 vectors (Invitrogen, Basel, Switzer-
land), one encoding the human κ light chain and the other the human γ1 heavy chain 
by using restriction digestion. The vectors encoding heavy and light chains were tran-
siently transfected into HEK293, and the cells were propagated in standard growing 
conditions. Large-scale purification of antibodies was performed using stably trans-
fected cells. HEK293 cells were co-transfected by using in-house prepared 1 mg/ml 
Materials and methods
Cloning, production, and purification
Cloning pcDNA3 vectors
4.1.
4.2.
4.2.1.
4.2.1.1.
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The method used for reformatting with MultiPrime was developed in our group by 
Mansouri et al. 2016152. The genes encoding VH and VL were inserted into a modi-
fied donor and acceptor vector, respectively, bearing the constant domains by using 
BamHI and XbaI restriction sites. Positive clones were selected by antibiotic screen-
ing. Integration of the donor expression cassette comprising the heavy chain (VH + 
CH) into acceptor vector bearing the light chain (VL + CL) was performed with Cre-
LoxP recombination152. In this way, both heavy and light chains were located on the 
same vector, having separate promotors (CMV) in separate expression units. IgGs 
were expressed in transiently transfected HEK293. Cells were grown in the stan-
dard growing conditions in large 15-cm plates in adherent cultures. When cultures 
reached confluency, cells were transiently transfected with MultiPrime bearing both 
heavy and light chains. Transfected cells were incubated at 37°C for 4 h, and the 
medium was then replaced with fresh mammalian cell culture medium.
Soluble full-length IgG antibodies were concentrated and filtered through a 0.45 μm 
filter (Millipore) and purified by protein A chromatography (GE). Buffers used for Pro-
tein A chromatography purification were: binding buffer: 20 mM Tris pH 8.0; washing 
buffer: 20 mM glycine pH 6.0 and elution buffer: 0.1 M glycine pH 2.5. The affinity chro-
matography purification was performed as previously described for scFvs in chapter 
2. Purified IgGs were concentrated and resolved on 12% and 7% SDS-PAGE gels.
FSEC, kinase activity assay, and tube formation assay were performed as previously 
described in chapter 2.8.11.
PEI (Polyethylenimine), and selection was performed after 24 h by adding 500 μg/ml of 
G418 (Geneticin) to the medium. Colonies were picked after 10 days. Stable HEK293 
cells were grown in 2 l shaking flasks in PEM (Protein Expression Medium, GIBCO) for 
2 weeks when 1M sodium butyrate was added to enhance protein expression. IgGs 
were purified from the filtered supernatant by Protein A chromatography.
4.2.2. FSEC, receptor kinase activity 
assay, tube formation assay
Reformatting with MultiPrime expression system
IgGs purification 
4.2.1.2.
4.2.1.3.
4.2.2.
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Results
IgG cloning and purification
Cloning into pcDNA3 vectors 
The most promising antibodies were converted into full-length IgGs consisting of 
light and heavy chains. Two different strategies were used to reformat scFvs to IgG.
First, the reformatting approach used allowed functional antibody production from 
stably transfected cells. Heavy and light chain variable regions from scFvs were PCR 
amplified using oligonucleotides (Table 4.1). Purified DNA was subcloned into two 
separate pcDNA3 vectors (Figure 4.1), one encoding human κ light chain and the 
other human γ1 heavy chain by using restriction digestion enzymes HindIII and Bsi-
Wi for VH and HindIII and NheI for VL. 
The DNA was sequenced using primers (Table 4.1). The vectors encoding heavy and 
light chains were transiently cotransfected into HEK293 cells propagated in stan-
dard growing conditions. Large-scale purification of antibodies was performed us-
ing stable transfection. When the cultures reached 60% cell confluency, they were 
transfected with PEI. After 4 h, transfection medium was replaced with fresh growing 
medium. 24 h later, the selecting antibiotic was added. The following days cell death 
and resistant cell colony formation was carefully observed. After 10 days, well-de-
fined colonies were picked and cultured separately. Colonies with the highest IgG 
expression were selected and used in large scale expression. 
IgGs were grown in large shaking flasks (2 l) in standard growing conditions in PEM 
media. Cell number was regularly monitored in order not to exceed 3 million cells/
ml. When culture reached 4 l it was filtered, concentrated and IgGs were purified us-
ing Protein A chromatography (Figure 4.3, A). The eluted peak fractions were loaded 
on 12% polyacrylamide gel and analyzed by Coomassie blue staining and anti-hu-
man IgG immunoblotting (Figure 4.3, B, C). The obtained yield for pcDNA3 strategy 
was ~1 mg from 1 l of culture.
4.3.
4.3.1.
4.3.2.
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Cloning with MultiPrime
MultiPrime approach was used to express functional antibodies in HEK293 cells. 
Cloning was performed in two steps (Figure 4.2). First, the genes encoding VH and VL 
were inserted into the modified donor and acceptor vector, respectively, bearing the 
constant domains by using BamHI and XbaI restriction sites. Subsequently, donor 
expression cassette bearing the DNA encoding the heavy chain was integrated into 
acceptor vector bearing the DNA encoding the light chain with Cre-LoxP recombina-
tion152. The cloning was performed with great help by Jonas Mechtersheimer.
Figure 4.1. Schematic representation of the pcDNA3 cloning workflow. VH and VL were PCR amplified with 
sequence addition of HindIII and BsiWI to VH and HindIII and NheI to VL DNA sequences. Digested DNAs 
were ligated to pcDNA3 vectors already bearing CH and CL, respectively. 
4.3.3.
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Figure 4.2. Schematic presentation of the MultiPrime cloning workflow. VH was ligated to acceptor vector 
already bearing CH and VL was ligated into donor vector already bearing CL. Full-length light chain (VL + CL) 
was fused to the donor containing full-length heavy chain (VH + CH). Acceptor-donor fusions are selected 
on plates with appropriate antibiotics, and verified by restriction mapping152. 
Table 4.1: Oligonucleotides used for IgG cloning into pcDNA3 vectors.
The single-host promoter CMV was utilized to drive recombinant IgG expression. The 
resulting MultiPrime vector was successfully tested for expression in HEK293. All IgG 
antibodies tested were expressed at comparable levels. HEK293 were propagated 
in adherent culture in standard conditions until reaching necessary cell number and 
density. Transient transfection was performed by using Lipofectamine 2000. Soluble 
IgGs were purified 48 h after transfection from filtered supernatant using Protein A 
chromatography as previously described (Figure 4.3, D). The eluted peak fractions 
were loaded on 12% polyacrylamide gel and analyzed with a Coomassie blue stain-
ing and anti-human IgG immunoblotting (Figure 4.3, E, F). The blots showed bands 
of the right size for both heavy (~50 kDa) and light chains (~25 kDa). Also, an un-
identified strong band of ~35 kDa could be observed for all purified IgGs. The yield 
obtained using MultiPrime strategy was ~1 mg from 250 ml of culture.
Primer 1 (melting temperatures) Primer 2 (melting temperatures)
VH gatcGCTCTTCCATGGGTTGGAGCCTCATC(67) catcGCTCTTCcTCAGGCTCAACTTTCTTGTCC(67)
VL gatcGCTCTTCCATGGAGACAGACACACTCCTG(68) catcGCTCTTCcTCAGACTCCGCCTTTCTTGGT(69)
Workﬂow of IgG reformating with MultiPrime
Selection
Veriﬁcation
Sequential insertion of addtional Donor(s) In vitro
Cre-loxP
recombination
5000 bp
2000 bp
1000 bp
600 bp
+
Maysam Mansouri 2016
IgG Heavy chain
Tn7L
Tn7R OriColE1
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Figure 4.3. A) & D) Purification profiles of IgG A7 obtained with MultiPrime and pcDNA 3 cloning strategies. 
B) & E) IgG proteins stained with Coomassie blue staining and C) & F) anti-human IgG antibody.
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Figure 4.4. IgG binding to recombinant VEGFR-2 in FSEC. A) FSEC analysis shows IgG A7 obtained with Multi-
Prime strategy binding VEGFR-2 ECD. The shift in the peak to the left (from red to blue peak) demonstrates the 
formation of a new, larger protein species in the combination of VEGFR-2 ECD and IgG A7. B) The shift from 
right to left is missing for IgG obtained with pcDNA3 strategy. C) To compare IgGs obtained with MultiPrime 
and pcDNA3 strategy obtained IgGs were resolved with SDS-PAGE. Coomassie blue staining and comparison 
of IgGs obtained with MultiPrime (MP), and pcDNA3 strategy shows the difference in size of the light chains. 
Determination of IgGs binding to VEGFR-2 
by FSEC
Thermodynamic analysis of antibody-VEGFR-2 interaction revealed a loss of binding 
in the case of IgGs using pcDNA3-based expression (Figures 4.4, B). IgGs cloned with 
MultiPrime maintained binding specificity towards hVEGFR-2 ECD (Figures 4.4, A). 
Coomassie blue staining of resolved IgG showed that the light chain from pcDNA3 
cloning strategy is shorter compared to the light chain from MultiPrime cloning (Fig-
ure 4.4, C). This may explain the lost binding proprieties. The same shorter band was 
observed in other cloned IgGs as well, indicating that there is probably a problem 
with the vector (pcDNA3) bearing the light chain. Again, an unidentified strong band 
of the size ~35 kDa could be observed for the purified IgGs (Figure 4.4, C).
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Functional inhibition of VEGFR-2 
phosphorylation with IgGs
We investigated the potential of IgG A7 to inhibit VEGFR-2 signaling in vitro. We ex-
posed PAE KDR cells to various concentrations of IgGA7 in the presence or absence 
of VEGF (Figure 4.5). Analysis revealed that IgG A7 significantly inhibited kinase phos-
phorylation at the Y1175 position, which was also reflected in reduced downstream 
signaling by PLCγ and AKT. P38 signaling did not show statistically significant change. 
4.3.5.
Figure 4.5. Effect of antibody treatment on VEGF-induced signaling in PAE KDR cells. A) scFvs effect on 
phosphorylation of VEGFR-2, PLCγ, AKT and p38. B) Quantification of western blot data. Quantification of 
data shown as n-fold increase over VEGF-induced signaling in the absence of antibodies. Data distribution 
and statistical analysis were performed using GraphPad, Prism 7. A representative experiment out of four 
independent experiments is shown. Error bars represent ± SD. The statistical significance based on a 
Student’s t-test is indicated by * representing P<0.05.
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Figure 4.6. Effect of antibody treatment on VEGF-induced capillary-like tube formation in HUVECs. A) Light 
microscopy of capillary-like tubes formed in the presence and absence of increasing concentrations of an-
tibodies. The total tube length was quantified with Wimasis online software (http://ibidi.wimasis.com/). B) 
Quantification of data shown as n-fold increase over VEGF-induced tube formation in the absence of anti-
bodies. Data distribution and statistical analysis were performed using GraphPad, Prism 7. A representative 
experiment is shown, out of three independent experiments. Error bars represent ± SD. The statistical 
significance based on a Student’s t-test is indicated by * representing P<0.05.
HUVEC tube formation assay
The effect of IgG A7 on the formation of capillary-like tubes by endothelial cells in 
Matrigel was examined. HUVEC were embedded in Matrigel and treated for 8 h 
with VEGF in the presence or absence of increasing concentrations of IgG A7. The 
formation of tubes was then examined under phase contrast microscopy. Results 
show that VEGF triggers the formation of a dense network of tubules when added 
to control HUVEC in Matrigel. This effect was markedly repressed in cells to which 
IgG A7 was added (Figure 4.6, A).  Four independent assays were performed for each 
concentration of IgG A7 and analyzed with ImageJ Angiogenesis analyzer software. 
Data was quantified with GraphPad (Figure 4.6, B).
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Discussion
Two methods were tested using MultiPrime and pcDNA3 expression vectors for the 
production of IgGs by using the natural dimerization mechanism between IgG heavy 
and light chains. The original VH or VL domains of an IgG molecule were replaced 
by scFvs, resulting in the full-length antibody. IgGs were functionally expressed and 
assembled in mammalian cells153. These two approaches are believed to be applica-
ble to a wide range of scFv antibodies. The small-size scFv fragments may be pref-
erable to the full-size IgG for some clinical applications, for example, to promote 
rapid clearance for improved tumor imaging55,56,89 and to facilitate efficient tumor 
penetration57. In many other applications, however, IgGs may offer additional advan-
tages as this format provides an IgG Fc region that can confer long serum half-life 
and support secondary immune functions154. The major hurdles in traditional meth-
ods of IgG production from scFvs include heterogeneity of the products, low yield, 
and difficulty with the purification process. For example, co-expression of IgG heavy 
and light chains gives different expression levels (Figure 4.3, E, F), compromising 
the yield of functional IgGs and imposing significant problems with purification. The 
first method for IgG production described herein (pcDNA3 method) provided pure 
IgG in high yield, but binding to VEGFR-2 ECD was lost. As discussed in the “Results” 
section, this probably occurred due to a cloning error in the pcDNA3 vector bearing 
the light chain sequence. A new method was recently developed to improve the pro-
duction of IgG-like molecules152. Mansouri et al. have demonstrated that MultiPrime 
bearing both heavy and light chains can be used to overcome non-uniform expres-
sion of heavy and light chains. IgGs expressed the with MultiPrime strategy retained 
the biological functions of scFvs. The IgGs bind the same target and efficiently neu-
tralize VEGF-induced VEGFR-2 phosphorylation in a dose-dependent manner. It is 
noteworthy that the IgGs are equally potent as scFvs in neutralizing VEGF-induced 
receptor phosphorylation. In HUVEC tube formation assay IgGs showed comparable 
inhibitory effect on total tube length. In conclusion, IgG antibodies were constructed 
from scFvs and characterized in vitro. Further, IgG A7 may be expressed in higher 
quantities with MultiPrime strategy and tested in mouse matrigel plug assay.
4.4.
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Selection and 
characterization of scFvs 
specific for the mouse 
VEGFR-2 ECD
5
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Before reaching humans, potential therapeutics must be tested in increasingly 
complex model systems ranging from cell culture to animal models, and such tests 
are still invaluable in discovering new technologies for the detection, management 
and treatment of cancer in humans. Preclinical research represents the evaluation 
of potential therapeutics in cells and animals. Regardless of ethical issues associ-
ated with in vivo studies, preclinical characterization remains a necessary step be-
fore propagating a therapy to the clinic155. The mouse (Mus musculus) represents 
one of the best model-systems for cancer investigations. The animals are small 
and show a good propensity to breed in captivity, they have a relatively short lifes-
pan of 3 years, extensive physiological and molecular similarities to humans, and 
an entirely sequenced genome156,157. Mouse cancer models offer several phases 
of increasing complexity, including xenograft tumors derived from human tumor 
cell lines or explants, chemical and viral carcinogens, and genetically engineered 
mice158. Each approach has its advantages and disadvantages, and it is important 
to choose the most appropriate system to address the particular questions. Im-
portantly, mouse cancer models represent a tremendous resource to evaluate 
the mechanism of malignancy. However, it is not always possible to extrapolate 
findings made in animal models to humans159.
One of the most appreciated properties of antibodies is their binding to their 
target antigen with high specific selectivity, which is a prerequisite for their use 
in targeted therapy160. By contrast, it is less common for antibodies to bind the 
corresponding antigen from a different species, although such binding is a desir-
able attribute that would facilitate preclinical evaluation of efficacy and toxicity. 
Success in generating such species-cross-reactive antibodies depends on the se-
quence-similarity of the antigen in different species, especially conservation of the 
binding epitope and the method of antibody generation. In theory, phage-display 
technology161 is particularly well suited for the generation of species-cross-reactive 
antibodies, because it is a fast and cheap method that circumvents immuniza-
tion of animals and allows screening and direct selection of species cross-reac-
tive antibodies162. In preclinical tumor angiogenesis models, human tumors are 
xenografed onto immunodeficient mice; the newly formed blood vessels in the 
transplanted tumor originate from the host (mouse), and conventional anti-hu-
man mAbs typically do not react with cell surface receptors displayed by mouse 
endothelial cells. In fact, the lack of cross-reactivity of humanized mouse mAbs 
directed to human integrin αvβ3 and human VEGFR-2 with the mouse antigen 
represents a major obstacle in their preclinical development163.
The specificity of VEGFR-2 expression, its location on the surface of the tumor ves-
sels, and its predominant role in tumor angiogenesis make it a highly desirable target 
for the development of both antiangiogenic and vascular targeting drugs130. Mouse 
tumor models represent a major testing system to evaluate such drugs. Models of 
murine tumor angiogenesis and receptor-specific antibodies are required to assess 
Introduction
5.1.
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the roles of VEGF receptors in mouse models of human cancer. Human VEGFR-2 
and murine VEGFR-2 share 85% amino acid sequence identity in their extracellular 
domain. The process of selection and characterization of anti-mouse-VEGFR-3 anti-
bodies for their use in in vivo studies is described below.
Purified mouse VEGFR-2 ECD was kindly provided by my colleague Mayanka 
Asthana. In brief, mouse VEGFR-2 ECD was expressed in transiently transfected 
HEK293-EBNA cells. ECD was purified by Ni-affinity chromatography (IMAC) and 
subsequently by size-exclusion chromatography (SEC). Purified protein was frozen 
at -80°C until further use.
Materials and methods
Production of recombinant mouse VEGR-2 
ECD
Selection of mouse specific scFvs against 
VEGFR-2
Anti-mouse VEGFR-2 scFvs were selected as previously described for human spe-
cific scFvs. 
Phage display selection was performed as previously described for mouse specific 
scFvs except that a glycerol stock of TG1 bacteria bearing scFvs, previously selected 
with hVEGFR-2, was used instead of the ETH-2 Gold library. 
Selection of mouse specific scFvs from ETH-2 Gold 
library
Selection of species cross-reactive scFv antibodies 
against mouse and human VEGFR-2 ECD
5.2.
5.2.1.
5.2.2.
5.2.2.1.
5.2.2.2.
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The R3 EPFL library was kindly provided by Prof. Christian Heinis from EPFL, Switzer-
land. The protein of interest was biotinylated using a biotinylation kit (21441, Thermo 
Scientific) and purified by PD-10 desalting columns (GE). The selection was performed 
in two rounds. In the first round, streptavidin beads were used, in the second, neutra-
vidin beads. 1 ml of the glycerol stock of bacteria bearing scFvs obtained from EPFL 
was grown in 2xYT media containing chloramphenicol. When the culture reached 
OD600 0.5, both IPTG (0.5 mM) and 300 μl VCS helper phage were added. After 30 min 
of incubation at 37°C, 20% glucose was added, followed by 1 h of shaking and the ad-
dition of kanamycin. ScFvs were grown overnight at 30°C when cultures were pelleted, 
and 20% PEG/2.5 M NaCl (200 ml) was added, after which the phage was allowed to 
precipitate at 0⁰C. Biotinylated target protein mVEGFR-2 was displayed on the surface 
of streptavidin beads (Thermo Scientific). Both phages and beads were blocked with 
blocking buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2, 0.1% 
Tween-20, 1% BSA). Blocked magnetic beads bearing biotinylated protein of interest 
were added to the blocked phages. The magnetic beads were washed extensively 
with buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2). The tubes 
were replaced every two washing steps to eliminate binders to plastic. In the last step, 
the selected scFvs were eluted with low pH of glycine buffer (50 mM glycine, pH 2.2) 
and pH was normalized with Tris Buffer (1 M Tris-Cl, pH 8). The phages were added to 
TG1 cells and incubated for 30 minutes at 37 °C. Cells were pelleted by centrifugation 
at 4000 rpm for 15 minutes, suspended in 2 ml 2YT and plated on a large agar 2YT/
chloramphenicol plate. The plate was incubated overnight at 37°C. The next day the 
colonies were scraped off the plate with 5 ml 2YT + 20% glycerol, frozen in liquid N2 
and stored as glycerol stock. ScFvs from the obtained glycerol stock were then purified 
for further use, in a procedure in which streptavidin beads were replaced with neutra-
vidin beads in order to discard streptavidin-specific scFvs.
Extracted DNA from the binders giving the strongest absorbance signal in ELISA 
assay was sent for sequencing to mycrosinth (http://www.microsynth.ch/) using se-
quencing primers. 
(LMB3 long: CAGGAAACAGCTATGACCATGATTAC and Fdseq long: GACGTTAGTAAAT-
GAATTTTCTGTATGAGG) and (primer 1: GGCTTCACCTTCAGCAGCTACG and primer 2: 
GCAGCACCTACTACGCCGATTC) for ETH-2 Gold library and R3 EPFL library respec-
tively. 
ScFvs bearing unique DNA sequences were produced in large scale expression and 
tested further.
Selection of mouse specific scFvs from R3 EPFL 
library
Sequencing of selected mouse scFvs
5.2.2.3.
5.2.3.
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For all isolated phagemid vectors, an initial test expression assay was performed in 
different E. coli strains (Mach1, BL21(DE3)). The culture was grown in 5 ml LB-AMP 
media inoculated with several colonies of transformed bacteria. The cultures were 
incubated at 37°C on a shaker until they reached an OD600 of 0.6 – 0.9. Protein ex-
pression was then induced with 1 mM IPTG final concentration. After incubation of 
the cultures overnight at 30°C on a shaker, they were centrifuged for 5 min (4000 
g; 4°C) and 20 μl of the supernatants were taken for analysis. The pellets were re-
suspended in 50 μl 3 M urea, incubated for 10 min at RT and centrifuged for 20 min 
(4000 g; 4°C). 20 μl aliquots of supernatants from the lysed cells were once again 
collected and analyzed by SDS-PAGE and western blot.
Testing protein expression to select 
optimal bacterial strain
Expression and purification of scFvs 
against mouse VEGFR-2
ScFv antibodies were expressed as previously described for human VEGFR-2 spe-
cific scFvs.
ScFv antibodies were expressed in E.coli Mach1. The bacteria were grown in 2xYT 
medium containing 100 μg/ml chloramphenicol and 0.1% glucose at 37°C until they 
reached an OD600 of 0.8. IPTG was added to a final concentration of 1 mM to induce 
expression of scFv antibodies. Following 10 hours of incubation at 30°C, the bacteria 
were pelleted by centrifugation at 4000 g for 20 min. Cell pellets were resuspended 
in lysis buffer with the addition of 1 mg/ml lysozyme, 20 μg/ml DNase and 2 com-
plete protease inhibitor tablets. The cells were homogenized with Turrax disperser 
(IKA) and lysed by high-pressure Emulsi-Flex C-3 (Avestin®) at 15000 psi. Unlysed 
cells, cell debris, and aggregates were removed by centrifugation at 17000 rpm for 
Expression and purification of soluble scFvs from 
ETH-2 Gold library
Expression and purification of scFvs from R3 EPFL 
library
5.2.4.
5.2.5.
5.2.5.1.
5.2.5.2.
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45 minutes. ScFvs were purified from the filtered supernatant by Protein A chroma-
tography. Typically, the obtained yield of scFvs from ETH-2 library was in the range 
of 1 – 4 mg from 1 l of bacterial culture and for scFvs obtained from R3 EPFL was ~1 
mg from 200 ml of bacterial culture.
Binder specificity was determined by enzyme-linked immunosorbent assay (ELISA) 
using immobilized recombinant mouse VEGFR-2 ECD protein D1-7, D1-3, D1-6. The 
assay was performed as previously described for human scFvs. 
Primary mouse hemangioma cells (mEnd) were kindly provided by Prof. Dr. Kiefer 
from University of Muenster. MEnd cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM; BioConcept, Basel, Switzerland) supplemented with 10% fetal bo-
vine serum (FBS) and 1% Penicillin–Streptomycin. Cells were propagated in a humid-
ified atmosphere at 37°C and 5% CO2.
The property of mEnd cells to form tube-like structures was used in tube formation 
assay, which was performed as previously described for HUVECs. 
In this kinase activity assay, mEnd cells were used to test mouse-specific scFvs. The 
assay was performed as previously described for scFvs against human VEGFR-2.
ELISA for binder specificity 
Cell culture
HUVEC tube formation assay
Receptor kinase activity assay
5.2.6.
5.2.7.
5.2.8.
5.2.9.
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Selection, production, and purification of scFv antibodies was performed as previous-
ly described in chapter 2. To determine VEGFR-2 binders, scFvs were tested in ELISA 
(Figure 5.1, A). The best binders were sent for sequencing and scFvs with unique 
sequences (Figure 5.1, B) were expressed in high yield, and tested further. Antibodies 
were purified from lysed cell pellets using Protein A chromatography (Figure 5.3, A). 
The eluted peak fractions were loaded on 12% polyacrylamide gel and analyzed with 
a Coomassie blue staining (Figure 5.3, B). The ScFvs from ETH-2 Gold library present-
ed here were selected by Nagjie Alijaj, with the exception of scFv MG6. 
ScFvs were selected against biotinylated mouse VEGFR-2 in two rounds from R3 EPFL 
library. Positive clones were chosen at random and tested for mVEGFR-2 specificity in 
ELISA (Figure 5.2, A). The binders with the best ELISA signal were sent for sequencing 
and scFvs with the unique DNA sequence (Figure 5.2, B) were expressed in large-
scale expression. ScFv antibodies were expressed in E.coli Mach1 grown in 2xYT me-
dium containing 100 μg/ml chloramphenicol and 0.1% glucose at 37°C until they 
reached an OD600 of 0.8. IPTG was added to a final concentration of 1 mM to induce 
expression of scFv antibodies. Antibodies were purified from lysed cell pellets with 
Protein A chromatography. 
Results
Selection, production, and purification of 
scFvs antibodies 
ETH-2 Gold library
R3 EPFL library
5.3.
5.3.1.
5.3.1.1.
5.3.1.2.
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Figure 5.1. ELISA screening of scFvs from ETH-2 Gold library. A) ELISA screening with mouse VEGFR-2 ECD 
D1 – D7 coated MaxiSorp® plates. Each 96-well plate was incubated with the supernatants of TG1 colonies 
selected through three rounds of phage display with the ETH-2 Gold library. B) Overview of mouse specific 
scFv CDR3 sequences with library variants and domain specificity.
scFv VH VL library Tag
Domain 
specificity
P1B9 PGANRT SGAFPA DP47 DPK22 myc D7
P1H1 PYVDRS AGSIPV DP47 DPK22 myc D7
P2A11 PSHGRS AGEFPP DP47 DPK22 myc D7
P2C1 PGPNRS SGNLPP DP47 DPK22 myc D7
P1G6 PHWQRA AGHSPV DP47 DPK22 myc D7
P1E8 PGPYRV SGMLPV DP47 DPK22 myc D7
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Figure 5.2. ELISA screening of scFvs from R3 EPFL library. A) ELISA screening with mouse VEGFR-2 ECD D1-D7 
coated MaxiSorp® plates. Each 96-well plate was incubated with the supernatants of TG1 colonies selected 
through two rounds of phage display with the R3 EPFL library. B) Overview of mouse specific scFv CDR3 
sequences with domain specificity.
scFv VH VL Tag
Domain 
specificity
A4 G G G P R E S P S P A myc D4-7
A6 L T G S H R R E N Y P Y myc D4-7
C7 P R S V S M Q F D P P A myc D4-7
E1 P Y S M R L S T I P S myc D4-7
E8 A R S L T F S Y R P A myc D4-7
F3 A Y S M K Y T H P R P T myc D4-7
F5 P Y S L T H D S V G P T myc D4-7
G1 P Y R V S M A Y T M E P L myc D4-7
H5 L Y S F R Y E R Y K P A myc D4-7
F3 A Y S M K Y T H P R P T myc D4-7
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Figure 5.3. Mouse specific scFv purification. A) Elution profile of scFv MG6 after purification by protein A chro-
matography. B) The eluted peak fractions loaded on 12% polyacrylamide gel and analyzed with a Coomassie 
blue staining.
ScFvs (1 µM) selected against mouse VEGFR-2 were tested in a kinase activity assay 
as previously described, using mEnd cells. Activity assay results failed to show that 
mouse-specific scFvs selected from ETH-2 Gold library inhibited kinase phosphory-
lation at Y1173 and downstream signaling (Figure 5.4). However, scFv ME8 selected 
from R3 EPFL inhibited Y1173 phosphorylation of VEGFR-2 (Figure 5.5). The expres-
sion and phosphorylation of PLCγ, AKT, and ERK were also examined, however, sig-
nificant inhibition of, downstream signaling for any of tested scFvs could not be con-
firmed. (Figure 5.5, A). All kinase assays were performed in triplicates and quantified 
with ImageJ software. Quantified data was analyzed with GraphPad (Figure 5.5, B).  
Functional inhibition of VEGFR-2 
phosphorylation with mouse specific scFvs
5.3.2.
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Figure 5.4. Testing of mouse specific scFvs obtained from ETH-2 Gold library. Effect of antibody treatment 
on VEGF-induced signaling in mEnd cells. A) The ability of scFvs (1 µM) to inhibit phosphorylation of VEG-
FR-2 and AKT was tested in mEnd cells. The western blot data was analyzed and quantified with Image J. B) 
Quantification of data shown as n-fold increase over VEGF-induced signaling in the absence of mouse-scFv 
antibodies. Data distribution and statistical analysis were performed using GraphPad, Prism 7.Data distribu-
tion and statistical analysis were performed using GraphPad, Prism 7. A representative experiment is shown, 
out of three independent experiments. Error bars represent ± SD. The statistical significance based on a 
Student’s t-test is indicated by * representing P<0.05.
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We examined the effect of scFvs on the formation of capillary-like tubes by endothe-
lial cells in Matrigel. mEnd cells were embedded in Matrigel and were treated for 8 
h with VEGF in the presence or absence of 1 µM of scFvs. Thereafter, the formation 
of tubes was examined in a phase contrast microscope. Results show that VEGF 
triggers the formation of a dense network of tubules when added to control mEnd 
in Matrigel. ScFv MA4 significantly repressed this effect when added (Figure 5.6). 
Effect of antibodies on endothelial cell 
tube formation 
5.3.3.
Figure 5.5. Testing of mouse specific scFvs obtained from R3 EPFL library. Effect of antibody treatment on 
VEGF-induced signaling in mEnd cells. A) The ability of scFvs (1 µM) to inhibit phosphorylation of VEGFR-2, 
PLCγ, AKT and ERK was tested in mEnd cells. The western blot data was analyzed and quantified with Image 
J. B) Quantification of data shown as n-fold increase over VEGF-induced signaling in the absence of mouse-
scFv antibodies. Data distribution and statistical analysis were performed using GraphPad, Prism 7. Data 
distribution and statistical analysis were performed using GraphPad, Prism 7. A representative experiment 
is shown out of three independent experiments. Error bars represent ± SD. The statistical significance based 
on a Student’s t-test is indicated by * representing P<0.05.
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Figure 5.6. Effect of antibody treatment on VEGF-induced capillary-like tube formation in mEnd cells. A) Light 
microscopy of capillary-like tubes formed in presence and absence of 1 µM of mouse-specific scFv antibod-
ies. The total tube length was quantified with Wimasis online software (http://ibidi.wimasis.com/) B) Quan-
tification of data shown as n-fold increase over VEGF-induced tube formation in the absence of antibodies. 
Data distribution and statistical analysis were performed using GraphPad, Prism 7.
Two phage display libraries were used to select mouse-specific scFvs against 
mVEGFR-2. From both libraries, we identified 16 scFvs that were shown to bind 
mVEGFR-2 ECD in ELISA. ME8 showed significant inhibition of VEGFR-2 Y1173 
phosphorylation. We also observed an inhibitory effect on endothelial cell tube 
formation with MA4. Further experiments to test these antibodies from both li-
braries should be performed in future projects. 
Possible applications of mouse-specific scFvs are numerous. Firstly, such antibod-
ies can be explored in preclinical tumor therapy164. By inhibiting VEGFR-2 activa-
tion, rapidly growing tumors would be deprived of nutrients and oxygen which 
would ultimately lead to tumor starvation and regression98,100.  Secondly, these 
scFvs could be used as delivering platforms for toxins67 and RNAs72. Thirdly, these 
antibodies can be useful reagents for monitoring the expression of the VEGFR-2 
protein in mouse tumor models or in models of other diseases where VEGFR-2 
plays a role and could potentially be utilized for vascular targeting and imaging58,89 
during tissue development. 
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Tumor targeting with 
radiolabeled DARPins
6
94 Dragana Avramović, Doctoral thesis
Lately, various antibody-based systems have been developed for noninvasive tumor 
imaging and tumor-targeted drug delivery16,55. VEGFR-2 is a major driver of angio-
genesis165 but it is also reported to be expressed in some cancer cell lines where 
it potentially plays a role in tumorigenesis166. Whether small antibody-like mole-
cules against VEGFR-2 can be used to target the tumor for imaging or drug deliv-
ery remains an open question. In this study, radiolabeled Designed Ankyrin Repeat 
Proteins (DARPins) and xenograft human tumors were used to address this issue. 
DARPins are recombinant binding proteins composed of ankyrin repeats, which 
stack together to make a contiguous binding surface167,168. Each ankyrin repeat con-
sists of 33 amino acids, which form a β-turn followed by two anti-parallel α-helices 
and a loop binding to the β-turn of the next ankyrin repeat. Synthetic DARPin librar-
ies have been designed, from which specific binders can be selected and further 
evolved by methods such as ribosome display169,170. Due to their high affinity, recep-
tor specificity and favorable molecular properties, DARPins offer application oppor-
tunities in diagnostic imaging and therapy using various conjugates171,172. The aim of 
this study was to evaluate the potential of 99mTc-labeled DARPins154,173,174 designed 
to target specific domains of the extracellular domain (ECD) of VEGFR-2 for in vivo 
molecular imaging of tumors104,175.
Introduction
A549 lung cancer cells and SW-480 colon carcinoma cells were maintained in Ham’s 
medium (Bioconcept). PAE KDR, Bovine aortic endothelial (BAE) cells, HeLa cervical 
carcinoma, OVCAR-3 ovarian cancer, SKOV-3 ovarian cancer, MCF-7 breast cancer 
and U87 glioblastoma cancer cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; BioConcept). Both media were supplemented with 10% fetal bo-
vine serum (FBS) and 1% Penicillin–Streptomycin. 
All DARPins were obtained from Molecular Partners (Schlieren, Switzerland) and 
were previously tested by our group104.
Materials and methods
Cell lines used in the study
DARPins 
6.1.
6.2.
6.2.1.
6.2.2.
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Cells propagated in standard culture conditions (described above) were detached 
from the plate surface by incubation with trypsin (GIBCO). The cell suspension con-
taining 500 000 cells was washed with PBS and blocked with 5% BSA for 1 h at 
room temperature. Cells were incubated with primary antibody against VEGFR-2 
(ab11939; Abcam) for 1 h at room temperature. After 3 washing steps with PBS, cells 
were incubated with fluorescently labeled secondary (1:10000) Dylight 488 antibody 
(Abcam) in PBS containing 5% BSA. Cells were sorted with FACS Aria™III (BD Biosci-
ences, Denmark) using the green fluorescent channel.
Excised tumor tissue was collected and frozen, embedded in TissueTek (O.C.T. Com-
pound; Sakura Finetek Europe B.V.), and stored at -80°C. Frozen tumors were cut 
into sections of 10 μm using a microtome (Cryo-Star HM 560 M), fixed in 4% parafor-
maldehyde for 20 min at RT and blocked for 20 min at RT with 5% BSA. The sections 
were then incubated with primary VEGFR-2 (ab11939; Abcam) or CD31 antibody 
(Abcam) overnight at 4°C, followed by exposure to DAB/H2O2 solution for visualiza-
tion. Images were obtained on an Olympus IX81 phase-contrast microscope. 
Commercially available molybdenum-99 (Mo-99) generator was used to obtain the 
decay product of Mo-99, Technetium-99 99mTc(CO)3. 1 ml of freshly eluted 99mTcO4 
was mixed with lyophilized sodium tartrate (8.5 mg), Na2B4O7•10H2O (2.85 mg), 7.15 
mg of sodium carbonate (7.15 mg) and sodium boranocarbonate (4.5 mg). The mix-
ture was then heated for 40 s at 150°C, and 350 μl neutralizing buffer solution (0.6 
M phosphate buffer, pH 7.0 / 1 N HCL, 3:2) was added. DARPins were mixed with 
99mTc(CO)3 in 0.125 M MES solution (pH 6.5), and the reaction was incubated at 37°C 
for 45 minutes. The final product was 100 μl at 30 MBq/μg DARPin. The quality con-
trol was performed by high-performance liquid chromatography (HPLC).
Fluorescence activated cell sorting (FACS)
Immunohistochemistry
Labeling of DARPins with 99mTc(CO)3
6.2.3.
6.2.4.
6.2.5.
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In vivo imaging
6 to 8 weeks old female athymic nude mice (CD-1 fox nu/nu) were purchased from 
Charles River Laboratories. (Sulzfeld, Germany). The animals were kept in standard 
housing conditions under a 12-hour light-dark cycle and provided with food and wa-
ter ad libitum. All animal procedures were approved by the Veterinary Department 
of the Canton Aargau, Switzerland and performed under the license No. 75528/2010 
issued to Dr. Eliane Fischer. 
Mice were injected subcutaneously (s.c.) with human SKOV-3.ip tumor cells subcuta-
neously injected at the lateral flanks with 6x106 SKOV-3 cells in 100 μl of PBS. When 
the tumors had reached a size of 0.5–1.5 cm3, approximately 21 days post inocula-
tion, the animals were randomly divided into groups (n = 4/group), and each group 
was subjected to a different radiolabeled DARPin derivative.
To specifically target tumors, two different approaches and two different protocols 
were used. First, two DARPins: HSA-06G9 and HSA-NI2C were used (See Table 1). 
Four animals were used per group. In the second protocol, 3 DARPins were used: 
HSA-06G9, HSA-06C8, and HSA-07H4 where one-half of the animals were pre-inject-
ed with a 20-fold higher concentration of cold (not radioactively labeled) 06G9, 06G9 
and 07H4 DARPins. The idea of the second approach was to block the specific signal 
with an excess of cold (unlabeled DARPins). 
Each mouse received a single dose of 10 μg of 99mTc(CO)3-labeled DARPin variant 
(300 MBq/mouse) intravenously, via the lateral tail vein in 100 μl PBS. Blocking stud-
ies were performed with a 20-fold excess of non-labeled DARPin in PBS and admin-
istered instantaneously before the radiotracer. Animals were anaesthetized under 
4% isoflurane at time intervals of 2 h, 4 h, or 24 h after injection and immediately im-
aged. Combined single photon emission computed tomography (SPECT) data were 
Animals
Cancer cell injections 
Tumor targeting with radiolabeled DARPins
SPECT/CT imaging 
6.2.6.
6.2.6.1.
6.2.6.2.
6.2.6.3.
6.2.6.4.
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acquired for 30 min and reconstructed images were generated using the LumaGEM 
software (version 5.407; Gamma-Medica Inc.). SPECT / computed tomography (CT) 
imaging experiments were performed with an X-SPECT system (Gamma-Medica Inc.) 
with a single-head SPECT camera and CT detector. SPECT data were acquired for 
30 min and reconstructed images were generated using the LumaGEM software 
(version 5.407; Gamma-Medica Inc.).
The animals were euthanized, and selected tissues and organs were collected, 
weighed, and checked for radioactivity in a γ-scintillation counter (Cobra II Packard). 
The results are presented as the percentage of the injected dose per gram of tissue 
weight (%ID/g), using reference counts from a definite sample of the original injec-
tate that was counted at the same time. 
Biodistribution
In this study, we used DARPin-derivatives (Table 6.1) which were additionally modi-
fied to carry a human serum albumin-binding entity (HSA) via unique cysteine cou-
pling at the COOH-terminal module. For the blocking study, we used DARPins previ-
ously characterized in our group. 
To select the most promising tumor model, we performed a FACS analysis to quan-
tify VEGFR-2 expression on the plasma membrane of a panel of tumor cell lines. 
The VEGFR-2 overexpressing PAE and BAE cell lines were chosen as the positive 
controls. The glioblastoma cell line U87 was chosen due to its reportedly high ex-
pression level of VEGFR-2 in vivo176. We detected membrane-bound VEGFR-2 in a 
sub-population of HeLa, MCF-7, SKOV-3 and OVCAR-3 cancer cell lines (Figure 6.1). 
Results
DARPins specificity MW (Da) Conc (g/l)
aHSA-06G9 D23 32727.70 11.7
aHSA-06C8 D4 32858.63 12.2
aHSA-07H4 D7 28949.32 9.5
aHSA-NI2C non-binding 29270.68 11.8
Table 6.1. Overview of biophysical properties of VEGFR-2 ECD targeting DARPins. 
6.2.7.
6.3.
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Figure 6.1. FACS analysis of membrane-bound VEGFR-2 on a panel of cancer cell lines.
Considering how the tumor microenvironment additionally influences protein ex-
pression in individual cells, an in vitro study does not necessarily correlate with in 
vivo expression profiles. For this purpose, tumors of palpable size were further an-
alyzed by immunohistochemistry. HeLa tumor sections were analyzed for VEGFR-2 
expression and the presence of blood vasculature by exposure to anti-VEGFR-2 and 
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Figure 6.2. VEGFR-2 and CD31 expression levels in mouse tumor models.
Figure 6.3. Radiochemical purity was determined by HPLC and revealed a single radiochemical peak cor-
responding to 99mTc-labeled DARPins. 
anti-CD31 antibodies (Figure 6.2). High level of CD31 expression is an indication 
of tumor angiogenesis. Tumor tissue sections showed the presence of VEGFR-2 
(brown) throughout the tumor mass, and tumor sections were CD31 positive.
To improve serum half-life, HSA-derivatives of each DARPin variant were selected. 
DARPins were labeled with 99mTc(CO)3 via the NH2-terminal his-tag at pH 6.5. Ra-
diochemical purity was confirmed by the presence of a single radiochemical peak 
(HPLC), revealing complete incorporation of 99mTc(CO)3 with no free reduction prod-
ucts; radiochemical yield was ≥95% for all radioconjugates (Figure 6.3). 
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Figure 6.4. SPECT/CT images and biodistribution of anti-VEGFR-2 99mTc-DARPins on SKOV-3 tumor-bearing 
mice. (A) SPECT/CT images of 99mTc-labled HSA-06G9 and NI2C. (B) Post-mortem biodistribution analysis.
Next, SPECT/CT imaging was performed on SKOV-3 tumor-bearing mice injected 
with radioactively labeled DARPins. A whole-body SPECT/CT of mice bearing tumors 
was performed 2, 4 and 24 hours after i.v. injection. The scans of mice injected with 
99mTc(CO)3-labeled VEGFR-2 targeting DARPins were compared with the scans of the 
mice injected with 99mTc(CO)3-labeled NI2C DARPin (Figure 6.4) or mice pre-injected 
with cold DARPin. (Figure 6.5). In all mice, high accumulation of radioactivity was 
detected in kidneys. Traceable radioactivity was detected in tumors, also in studies 
with non-binding DARPins (NI2C) and in the control group injected with an excess 
of cold DARPins.
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Figure 6.5. SPECT/CT images and biodistribution of anti-VEGFR-2 99mTc(CO)3-DARPins on SKOV-3 tumor-bear-
ing mice. (A) SPECT/CT images of 99mTc(CO)3HSA-06G9, HSA-06C8, and HSA-07H4. (B) Post-mortem biodis-
tribution analysis.
The goals of this study were to quantitatively test the ability of DARPins to target xe-
nografed tumors in mice, examine if the optimal tumor-targeting format of DARPin 
is the HSA-derivative and evaluate if VEGFR-2 can be used as a tumor marker for in 
vivo imaging174. Due to its high affinity and small size, it was proposed that DARPins 
would be efficient tools for in vivo imaging172 of xenograft tumors. In a pilot study 
(data not shown) fast blood clearance of DARPins was observed. Therefore, DARPin 
derivatives which contained an additional serum albumin binding entity attached to 
their C-terminus were employed. Although HSA-derivatives significantly prolonged 
blood circulation with notable levels of radioactivity still present at 24 h post in-
jection, the increase in size due to the serum albumin-binding entity also led to 
non-specific accumulation in the tumor. To address this issue a second study was 
performed with the goal to block specific tumor intake177. However, no specific 
blocking of the radioactive signal in tumors was demonstrated.
A possible explanation is that the performance of DARPins in vivo was not as de-
scribed in vitro and that DARPins simply don’t reach VEGFR-2 in tumors in the mouse 
model used. High radioactivity in liver and kidney gives information about the elim-
ination pathway of the DARPins. As expected, the small DARPins are predominant-
ly eliminated via the kidney. High kidney values are observed for all monovalent 
DARPins, similar to scFv fragments173,178,179 and camel VHH domains
180. Second pos-
sible explanation could be that the level of VEGF-2 expressed in SKOV-3 xenograft 
tumors was not high enough. To conclude, we failed to show that highly specific in 
vitro validated VEGFR-2 DARPins represent a potential tool for tumor imaging.
Discussion
6.4.
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The concept that tumors are dependent on surrounding blood vessels and the idea 
that inhibiting the formation of new blood vasculature in cancer might inhibit the 
tumor appeared almost 40 years ago. Since then, a variety of anti-angiogenic drugs 
have been developed, and many of them have entered clinical trials. A promising 
target for anti-angiogenic therapies remains VEGFR-2, as the primary mediator of 
angiogenic signaling. Inhibiting VEGFR-2 is the main goal of this thesis. Although 
the evident purpose of this work was aimed at tumor angiogenesis inhibition, the 
inhibitors characterized herein, could be used for other angiogenesis-dependent 
conditions such as macular degeneration, diabetic retinopathy, atherosclerosis, 
rheumatoid arthritis, and other diseases. The study comprised generation and char-
acterization of novel binders to the ECD of VEGFR-2 in different antibody formats 
such as scFvs, Fabs and IgGs that bind to D23, D6 or D7 and inhibit VEGFR-2 in an 
allosteric fashion not interfering with ligand-binding. The inhibitors in scFv, Fab, and 
IgG formats could have potential in clinical applications such as in tumor vasculature 
imaging, or as drug delivery platforms to inhibit angiogenesis. Imaging in live mice 
could be carried out with different technologies such as positron emission tomog-
raphy (PET) or single-photon emission computed tomography (SPECT) using tagged 
variants of the scFvs and Fabs. Bioconjugation of the scFv to drugs for site-specific 
delivery of these drugs represents another possible use. Furthermore, the poten-
tial of using the full-length IgGs as angiogenesis inhibitors in vivo can be tested in 
HUVEC plug assays181 in mouse models. In the end, the ability of DARPins to target 
xenografed tumors in mice was quantitatively tested and it was examined if the op-
timal tumor targeting format of DARPin is the HSA-derivative; it was also evaluated 
whether VEGFR-2 can be used as a tumor marker for in vivo imaging174. In two in vivo 
studies, it was not demonstrated that the highly VEGFR-2 specific DARPins would be 
promising tools for tumor imaging. The inhibitors described herein should be test-
ed for application in VEGFR-2-induced ophthalmic pathologies and might represent 
alternatives to existing VEGF-inhibitory drugs182-184.
Conclusions and Outlook 
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